Element Solutions (ESI) 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 12, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Platform Specialty Products Corp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding (in shares)		210,864,903
Amendment Flag	false
Entity Central Index Key	1,590,714
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Net sales	$ 675.1	$ 189.1	$ 1,209.9	$ 372.8
Cost of sales	406.5	92.4	734.2	191.9
Gross profit	268.6	96.7	475.7	180.9
Operating expenses:
Selling, technical, general and administrative	206.2	85.2	398.2	159.2
Research and development	18.4	5.9	31.3	12.1
Total operating expenses	224.6	91.1	429.5	171.3
Operating profit	44	5.6	46.2	9.6
Other (expense) income:
Interest expense, net	(51.1)	(7.7)	(90.5)	(15.4)
Other (expense) income, net	(2.2)	(0.5)	33.4	(0.6)
Total other expense	(53.3)	(8.2)	(57.1)	(16)
Loss before income taxes and non-controlling interests	(9.3)	(2.6)	(10.9)	(6.4)
Income tax benefit (expense)	0.2	4.1	(24.5)	1.9
Net (loss) income	(9.1)	1.5	(35.4)	(4.5)
Net income attributable to the non-controlling interests	(3.1)	(1.9)	(3.5)	(3.3)
Net loss attributable to common stockholders	$ (12.2)	$ (0.4)	$ (38.9)	$ (7.8)
Loss per share
Basic (in usd per share)	$ (0.06)	$ 0	$ (0.20)	$ (0.07)
Diluted (in usd per share)	$ (0.06)	$ 0	$ (0.20)	$ (0.07)
Weighted average shares outstanding
Basic (in Shares)	192.8	128.6	192.3	117.9
Diluted (in Shares)	192.8	128.6	192.3	117.9

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (9.1)	$ 1.5	$ (35.4)	$ (4.5)
Foreign currency translation adjustments
Foreign currency translation adjustments	161.5	19.7	(263.7)	23
Pension and post-retirement plans
Net loss recognized during the year	0	0	0	0.2
Pension and post-retirement plans	0	0	0	0.2
Tax expense	0	0	(0.5)	0
Pension and post-retirement plan, net of tax	0	0	(0.5)	0.2
Unrealized gain on available for sale securities
Unrealized gain on available for sale securities	0.3	0.1	0.2	0
Tax expense	0	0	0	0
Unrealized gain on available for sale securities, net of tax	0.3	0.1	0.2	0
Derivative financial instruments revaluation
Unrealized hedging loss arising during the period	0	(0.2)	0	(0.2)
Derivative financial instruments revaluation	0	(0.2)	0	(0.2)
Tax benefit	0	0.1	0	0.1
Derivative financial instruments revaluation, net of tax	0	(0.1)	0	(0.1)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Total other comprehensive income (loss), net of tax	161.8	19.7	(264)	23.1
Comprehensive income (loss)	152.7	21.2	(299.4)	18.6
Comprehensive (income) loss attributable to the non-controlling interests	(4.7)	(3.2)	3.6	(4.6)
Comprehensive income (loss) attributable to common stockholders	$ 148	$ 18	$ (295.8)	$ 14

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 672.2	$ 397.3
Restricted cash	0	600
Accounts receivable, net of allowance for doubtful accounts of $12.4 and $9.6 at June 30, 2015 and December 31, 2014, respectively	1,050.1	327.3
Inventories	470	205.8
Prepaid expenses and other current assets	195	46.1
Total current assets	2,387.3	1,576.5
Property, plant and equipment, net	280.6	175
Goodwill	3,012.8	1,405.3
Intangible assets, net	2,777.3	1,341.5
Other assets	88.4	49
Total assets	8,546.4	4,547.3
Liabilities & Stockholders' Equity
Revolving credit facilities	22.4	0
Current installments of long-term debt	16.8	13.2
Accounts payable	386.7	106.7
Accrued salaries, wages and employee benefits	30.3	31.3
Accrued income taxes payable	1.5	16.7
Accrued working capital adjustment payable	0	14.3
Accrued customer rebates and sales incentives	139.5	9.9
Financial guarantees and factoring	70	0
Other current liabilities	190.8	48.6
Total current liabilities	858	240.7
Long-term debt and capital lease obligations	3,401.6	1,392.4
Long-term retirement benefits, less current portion	45.2	38.8
Long-term deferred income taxes	675.6	202.3
Long-term contingent consideration	67.5	63.9
Other long-term liabilities	104.1	56.6
Total liabilities	$ 5,152	$ 1,994.7
Commitments and contingencies (Note 15)
Redeemable preferred stock - Series B	$ 645.9	$ 0
Stockholders' Equity
Preferred stock - Series A	0	0
Common stock, $0.01 par value per share (effective January 23, 2014), 400,000,000 shares authorized, 210,861,044 and 182,066,980 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	2.1	1.9
Additional paid-in capital	3,287.9	2,812.4
Accumulated deficit	(263)	(224.1)
Accumulated other comprehensive loss	(387.6)	(130.6)
Total stockholders' equity	2,639.4	2,459.6
Non-controlling interests	109.1	93
Total equity	2,748.5	2,552.6
Total liabilities, redeemable preferred shares and equity	$ 8,546.4	$ 4,547.3

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Accounts receivable, allowance for doubtful accounts (in Dollars)	$ 12.4	$ 9.6
Common shares, par value (in usd per share)	$ 0.01	$ 0.01
Common shares authorized (in shares)	400,000,000	400,000,000
Common shares issued (in shares)	210,861,044	182,066,980
Common shares outstanding (in shares)	210,861,044	182,066,980

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Adjustments to reconcile net loss from operations to net cash flows (used in) provided by operating activities:
Net cash flows provided by operating activities	$ 100.3	$ 49.2
Cash flows from investing activities:
Capital expenditures, net	(29.3)	(4.6)
Change in restricted cash	600	0
Acquisition of businesses, net	(2,856.7)	4.8
Investment in registrations of products	(14.6)	0
Other, net	0.1	0
Net cash flows (used in) provided by investing activities	(2,300.5)	0.2
Cash flows from financing activities:
Proceeds from issuance of debt, net of discount and premium	2,082.7	0
Change in revolving credit facilities, net	7.1	0
Repayments of borrowings	(10.3)	(3.8)
Proceeds from issuance of common stock, net	469.4	473.6
Payment of debt financing fees	(45.5)	0
Change in factored liabilities	(18.9)	0
Other, net	(0.6)	0.2
Net cash flows provided by financing activities	2,483.9	470
Effect of exchange rate changes on cash and cash equivalents	(8.8)	0.3
Net increase in cash and cash equivalents	274.9	519.7
Cash and cash equivalents at beginning of period	397.3	123
Cash and cash equivalents at end of period	$ 672.2	$ 642.7

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Changes in Stockholders' Equity Statement - USD ($) $ in Millions	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Parent [Member]	Noncontrolling Interest [Member]	Exchange of Warrants [Member]	Exchange of Warrants [Member]Common Stock [Member]	Exchange of Warrants [Member]Additional Paid-in Capital [Member]	Exchange of Warrants [Member]Parent [Member]	United States Postretirement Benefit Plan of US Entity [Member]	United States Postretirement Benefit Plan of US Entity [Member]Common Stock [Member]	United States Postretirement Benefit Plan of US Entity [Member]Additional Paid-in Capital [Member]	United States Postretirement Benefit Plan of US Entity [Member]Parent [Member]	IPO [Member]	IPO [Member]Common Stock [Member]	IPO [Member]Additional Paid-in Capital [Member]	IPO [Member]Parent [Member]
Beginning balance, shares (in Shares) at Dec. 31, 2013		2,000,000	103,571,941
Beginning balance, stockholders' equity at Dec. 31, 2013	$ 1,115.1	$ 0	$ 0	$ 1,212	$ (194.2)	$ 1.3	$ 1,019.1	$ 96
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(5.9)				(7.4)		(7.4)	1.5
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	3.4		0	0	0	3.4	3.4	0
Issuance of common stock to former non-founder director for exercise of stock options		$ 0	$ 1	(1)
Issuance of stock, shares (in Shares)			3,959
Issuance of stock	0			0			0
Exercise of warrants for common shares (in shares)										14,992,950
Exercise of warrants for common shares									$ 172.5	$ 0.2	$ 172.3	$ 172.5
Issuance of common shares with 401 (k) (in shares)														1,670,386
Issuance of common shares with 401 (k)													$ 18.4	$ 0	$ 18.4	$ 18.4
Distribution to non-controlling interest	(0.2)							(0.2)
Ending balance, shares (in Shares) at Mar. 31, 2014		2,000,000	120,239,236
Ending balance, stockholders' equity at Mar. 31, 2014	1,303.3	$ 0	$ 1.2	1,401.7	(201.6)	4.7	1,206	97.3
Beginning balance, shares (in Shares) at Dec. 31, 2013		2,000,000	103,571,941
Beginning balance, stockholders' equity at Dec. 31, 2013	1,115.1	$ 0	$ 0	1,212	(194.2)	1.3	1,019.1	96
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(4.5)
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	23.1
Ending balance, shares (in Shares) at Jun. 30, 2014		2,000,000	137,290,980
Ending balance, stockholders' equity at Jun. 30, 2014	$ 1,626.3	$ 0	$ 1.4	1,703.5	(202)	23.1	1,526	100.3
Price of shares issued (in usd per share)	$ 11								$ 11.50
Beginning balance, shares (in Shares) at Mar. 31, 2014		2,000,000	120,239,236
Beginning balance, stockholders' equity at Mar. 31, 2014	$ 1,303.3	$ 0	$ 1.2	1,401.7	(201.6)	4.7	1,206	97.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	1.5				(0.4)		(0.4)	1.9
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	19.7					18.4	18.4	1.3
Issuance of stock, shares (in Shares)			15,800,000
Issuance of stock	300.2		$ 0.2	300			300.2
Exercise of warrants for common shares (in shares)										1,251,744
Exercise of warrants for common shares	(13.4)			(13.4)	0	0	(13.4)	0	$ 14.4	$ 0	14.4	14.4
Recovery of short swing profits, net	0.5			0.5	0	0	0.5	0
Equity compensation expense	0.3			0.3	0	0	0.3	0
Distribution to non-controlling interest	(0.2)							(0.2)
Ending balance, shares (in Shares) at Jun. 30, 2014		2,000,000	137,290,980
Ending balance, stockholders' equity at Jun. 30, 2014	$ 1,626.3	$ 0	$ 1.4	1,703.5	(202)	23.1	1,526	100.3
Price of shares issued (in usd per share)	$ 19,000,000
Beginning balance, shares (in Shares) at Dec. 31, 2014		2,000,000	182,066,980
Beginning balance, stockholders' equity at Dec. 31, 2014	$ 2,552.6	$ 0	$ 1.9	2,812.4	(224.1)	(130.6)	2,459.6	93
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(26.3)				(26.7)		(26.7)	0.4
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	(425.9)					(417.2)	(417.2)	(8.7)
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014			10,050,290
Issuance of common stock to former non-founder director for exercise of stock options		$ 0	$ 0	0.9
Issuance of common shares to directors for exercise of stock options, value	0.9						0.9	0
Issuance of common shares to directors for exercise of stock options (in shares)			75,000
Issuance of stock, shares (in Shares)			21,316
Issuance of stock	0			0.2			0.2	(0.2)
Exercise of warrants for common shares (in shares)										7,986
Exercise of warrants for common shares									0.1	$ 0	0.1	0.1
Issuance of common shares with 401 (k) (in shares)														0
Issuance of common shares with 401 (k)													0.7	$ 0	0.7	0.7
Acquisition of non-controlling interest with Arysta Acquisition	24.6							24.6
Ending balance, shares (in Shares) at Mar. 31, 2015		2,000,000	192,221,572
Ending balance, stockholders' equity at Mar. 31, 2015	2,126.7	$ 0	$ 1.9	2,814.3	(250.8)	(547.8)	2,017.6	109.1
Beginning balance, shares (in Shares) at Dec. 31, 2014		2,000,000	182,066,980
Beginning balance, stockholders' equity at Dec. 31, 2014	2,552.6	$ 0	$ 1.9	2,812.4	(224.1)	(130.6)	2,459.6	93
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(35.4)
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	$ (264)
Issuance of common shares to directors for exercise of stock options (in shares)	75,000
Ending balance, shares (in Shares) at Jun. 30, 2015		2,000,000	210,861,044
Ending balance, stockholders' equity at Jun. 30, 2015	$ 2,748.5	$ 0	$ 2.1	3,287.9	(263)	(387.6)	2,639.4	109.1
Beginning balance, shares (in Shares) at Mar. 31, 2015		2,000,000	192,221,572
Beginning balance, stockholders' equity at Mar. 31, 2015	2,126.7	$ 0	$ 1.9	2,814.3	(250.8)	(547.8)	2,017.6	109.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(9.1)				(12.2)		(12.2)	3.1
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014	161.8					160.2	160.2	1.6
Issuance of stock, shares (in Shares)			406,217															18,226,414
Issuance of stock	0			4.7			4.7	(4.7)									$ 483	$ 0.2	$ 482.8	$ 483
Exercise of warrants for common shares (in shares)										6,841
Exercise of warrants for common shares	(14.8)			(14.8)	0	0	(14.8)	0	$ 0.3	$ 0	$ 0.3	$ 0.3
Issuance of common shares with 401 (k)													$ 0.6		$ 0.6	$ 0.6
Ending balance, shares (in Shares) at Jun. 30, 2015		2,000,000	210,861,044
Ending balance, stockholders' equity at Jun. 30, 2015	$ 2,748.5	$ 0	$ 2.1	$ 3,287.9	$ (263)	$ (387.6)	$ 2,639.4	$ 109.1
Price of shares issued (in usd per share)	$ 26.50								$ 11.50

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Platform Specialty Products Corporation is a global, diversified producer of high-technology specialty chemical products. The Company's business involves the formulation of a broad range of solutions-oriented specialty chemicals, which are sold into multiple industries, including agrochemical, animal health, electronics, graphic arts, plating, and offshore oil production and drilling. The Company refers to its products as “dynamic chemistries” due to their intricate chemical compositions. As further described in Note 20, Segment Information, the Company operates in two segments: Performance Applications and Agricultural Solutions. Platform was originally incorporated with limited liability under the laws of the British Virgin Islands under the BVI Companies Act on April 23, 2013. Until the MacDermid Acquisition on October 31, 2013, as described below, the Company had neither engaged in any operations nor generated any income. On October 31, 2013, the Company completed the MacDermid Acquisition pursuant to which it indirectly acquired substantially all of the equity of MacDermid Holdings, which, at the time, owned approximately 97% of MacDermid. The Company acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement. On January 22, 2014, the Company completed its Domestication and on January 23, 2014, the Company's common stock, par value $0.01 per share, began trading on the NYSE under the ticker symbol “PAH.” Basis of Presentation These unaudited interim Condensed Consolidated Financial Statements and related information have been prepared in accordance with U.S. GAAP for interim financial information and in accordance with the applicable rules and regulations of the SEC. Accordingly, they do not include all of the disclosures required in connection with annual financial statements. These unaudited interim Condensed Consolidated Financial Statements reflect all adjustments that are, in the opinion of management, normal, recurring and necessary for a fair statement of the results of operations. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included in the Company’s Annual Report. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements, but does not include all footnote disclosures from the annual financial statements. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include Platform's accounts and all of its controlled subsidiaries. All subsidiaries are included in the Condensed Consolidated Financial Statements for the entire period or, if acquired, from the date that the Company obtains control. The Company fully consolidates the income, expenses, assets, liabilities and cash flows of subsidiaries from the date it acquires control up to the date control ceases. All intercompany accounts and transactions were eliminated in consolidation. Significant Accounting Policies Marketable Equity Securities Equity securities that have a readily determinable fair value are classified as available for sale and are carried at fair value. Unrealized holding gains and losses are recorded in other comprehensive income. Equity securities which do not have readily determinable fair values are recorded at cost, and are evaluated whenever events or changes in circumstances indicate that the carrying values of such investments may be impaired. Financial Guarantees and Factoring of Accounts Receivable Guarantees provided to financial institutions on vendor and customer loans used to settle outstanding accounts receivable balances are recorded as liabilities until such time when the guarantee periods have elapsed, at which time the accounts receivable balances and the related financial guarantees are reversed. Factoring arrangements, where substantially all economic risks and rewards associated with trade receivables are transferred to a third party, are accounted for by derecognizing the trade receivables upon receiving the cash proceeds from the factoring arrangement. Factoring arrangements, where some, but not substantially all economic risks and rewards are transfered to a third party and where the assets subject to the factoring remain under the Company's control are accounted for by not derecognizing the trade receivables and by recognizing any related obligations to the third party. Product Registrations Product registrations represent external costs incurred to obtain distribution rights from regulatory bodies for certain products in our Agricultural Solutions segment. These costs include laboratory testing, legal, regulatory filing and other costs. Only costs associated with products that are probable of generating future cash flows are capitalized. The capitalized costs are amortized over the useful life of the registrations and are included in "selling, technical, general and administrative" expenses in the Condensed Consolidated Statement of Operations and are evaluated for impairment in the same manner as other finite-lived intangible assets. Equity Method Investments Investments in which the Company has the ability to exercise significant influence over, but does not control, are accounted for under the equity method of accounting and are included in "other assets" on the Condensed Consolidated Balance Sheet. Significant influence generally exists when the Company holds between 20% and 50% of the voting power of another entity. Investments are initially recognized at cost. The Condensed Consolidated Financial Statements include the Company's share of net earnings or losses from the date that significant influence commences until the date that significant influence ceases. When the Company's share of losses exceeds its interest in an equity investment, the carrying amount of that interest is reduced to zero, and the recognition of further losses is discontinued, except to the extent that the Company has an obligation or has made payments on behalf of the investee. Revenue Recognition The Company recognizes revenue, including freight charged to customers, net of applicable rebates, estimates for sales returns and allowances and discounts, when the earnings process is complete. This occurs when products have been shipped to or received by the customer, in accordance with the terms of the agreement, title and risk of loss has been transferred, pricing is fixed or determinable and collectability is reasonably assured. The Company allows certain distributors within the Agricultural Solutions segment one-time, non-repeatable extensions of credit on a limited portion of purchases made during a purchasing cycle, which remain in the distributor’s inventory. The extension of credit is not a right to return, and distributors must pay unconditionally when the extended credit period expires. Accounting Policies Recently Adopted and Pending Pronouncements Revenue from Contracts with Customers (Topic 606) - In August 2015, the FASB issued ASU No. 2015-14 “Deferral of the Effective Date,” which defers the effective date of ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)," for all entities by one year. As a result, the provisions of ASU No. 2014-09 will be effective prospectively for fiscal years and interim periods beginning after December 15, 2017. ASU No. 2014-09 (1) removes inconsistencies and weaknesses in revenue requirements, (2) provides a more robust framework for addressing revenue issues, (3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, (4) provides more useful information to users of financial statements through improved disclosure requirements and (5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company continues to evaluate the impact of this ASU. Inventory (Topic 330) - In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory.” Under the updated guidance, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is in the process of evaluating the impact of this new ASU, but does not expect it to have a material impact on its financial statements. Fair Value Measurement (Topic 820) - In May 2015, the FASB issued ASU No. 2015-07, “ Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent).” This update eliminates diversity in practice related to investments whose fair value is measured using net asset values as a practical expedient, and removes the requirement to categorize such investments within the fair value hierarchy. The guidance is effective retrospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company continues to evaluate the impact of this new ASU, but does not expect it to have a material impact on its financial statements. Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40 ) - In April 2015, the FASB issued ASU No. 2015-05, “ Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.” This update provides explicit guidance to customers utilizing a cloud computing solution to help determine whether such an arrangement include a software license, in which case the accounting applied would be similar to that of other software license arrangements. Otherwise, the arrangement would be accounted for as a service contract. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Interest - Imputation of Interest (Subtopic 835-30) - In April 2015, the FASB issued ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs.” This update eliminates the difference in the presentation of debt issuance costs and debt discount and premiums by requiring that debt issuance costs be presented as deductions from the carrying value of the related debt, in a manner similar to debt discounts. The guidance is effective retroactively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company adopted this ASU as of June 30, 2015, and reclassified approximately $48.6 million and $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of June 30, 2015 and December 31, 2014, respectively. Derivatives and Hedging (Topic 815) - In November 2014, the FASB issued ASU No. 2014-16, “ Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force).” Under current practice, there were predominantly two methods used to evaluate whether the nature of the host contract in a hybrid financial instrument is more akin to debt or equity: one considered all the features including the embedded and the other excluded the embedded derivative in the consideration. This update eliminates the difference in practice by clarifying that the evaluation should be based on all the instrument’s features, including the embedded derivative, and that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. The guidance is effective for fiscal years and interim periods beginning after December 15, 2015 and is applied in a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of our fiscal year 2016. Early adoption, including in an interim period, is permitted. The Company adopted the provision of this ASU during the first quarter of 2015, with the issuance of the Series B Convertible Preferred Stock. This ASU did not have a material impact on the Company's financial statements, as there were no hybrid financial instruments requiring retrospective application. Out of Period Adjustment In connection with the preparation of the Company's Condensed Consolidated Financial Statements for the period ended June 30, 2015, the Company identified a prior period error related to foreign currency accounting within Arysta and purchase accounting for the Arysta acquisition in accordance with ASC 805 - Business Combinations for the period ended March 31, 2015. The Company determined that goodwill was understated and foreign currency translation adjustment loss was overstated by approximately $73.0 million . Based on an analysis of qualitative and quantitative factors, management has concluded that this error was not material to the Company's Condensed Consolidated Financial Statements for the period ended March 31, 2015 or June 30, 2015. As a result, the affected balances were corrected in the Condensed Consolidated Financial Statements for the period ended June 30, 2015. Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation.

Acquisitions of Businesses

Acquisitions of Businesses	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Acquisitions of Businesses	ACQUISITIONS OF BUSINESSES Arysta Acquisition On February 13, 2015, we completed the Arysta Acquisition for approximately $3.50 billion , consisting of $2.86 billion in cash (net of acquired cash, closing adjustments and including Seller transaction expenses paid by Platform) and the issuance to the Seller of $600 million of Platform’s Series B Convertible Preferred Stock with a fair market value of $646 million . We acquired Arysta to expand our presence in the agrochemical business, complementing our acquisitions of Agriphar and CAS. Arysta provides products and solutions utilizing globally managed patented, proprietary off-patent agrochemical AIs and biological solutions, or biosolutions, and off-patent agrochemical offerings. Biosolutions includes biological stimulants, or biostimulants, innovative nutrition and biological control, or biocontrol, products. Arysta is included in the Company's Agricultural Solutions business segment. In connection with the Arysta Acquisition, the Company incurred $4.9 million and $27.8 million in related expenses for the three and six months ended June 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $6.4 million in related expenses through December 31, 2014. CAS Acquisition On November 3, 2014, we completed the CAS Acquisition for $1.04 billion , consisting of $983 million in cash, net of acquired cash and certain post-closing working capital and other adjustments, and 2,000,000 shares of our common stock. Due to regulatory constraints, title to certain CAS businesses located in Russia was not transferred to Platform until the first quarter of 2015. In connection with the CAS Acquisition, the Company entered into six supply agreements with Chemtura to supply the Company certain products, on an exclusive basis. These arrangements included capital leases for certain equipment totaling $13.2 million , which were recorded as of June 30, 2015. This measurement period adjustment had a cumulative impact to depreciation of $2.2 million which was recorded in the three months ended June 30, 2015 as the impact on the three months ended March 31, 2015 and the year ended December 31, 2014 was not material. In addition, we have agreed to fund the asset retirement obligations associated with the related equipment. Accordingly, we have recognized an asset retirement obligation of $13.2 million . The agreements will remain in force until either party provides advance termination notice, with a minimum term of four years. In line with our business strategy of growing into niche markets and applications, we acquired CAS to enter the agrochemical industry. CAS is a niche provider of seed treatments and crop protection applications in numerous geographies across seven major product lines - adjuvants, fungicides, herbicides, insecticide, miticides, plant growth regulators and seed treatments. CAS is included in the Company's Agricultural Solutions business segment. In connection with the CAS Acquisition, the Company incurred $4.9 million and $9.8 million in related expenses for the three and six months ended June 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $33.9 million in related expenses through December 31, 2014. Agriphar Acquisition On October 1, 2014, we completed the Agriphar Acquisition for a purchase price of approximately €300 million ( $370 million ), consisting of $350 million in cash, net of acquired cash and certain post-closing working capital and other adjustments, and 711,551 restricted shares of our common stock. Such restricted shares will become unrestricted beginning January 2, 2018, unless agreed otherwise in accordance with the terms of the acquisition agreement. The agreement also stipulates that prior to January 2, 2018, the seller may transfer (i) a maximum of 1/3 of its shares as of January 2, 2016, (ii) 1/3 of its shares as of January 2, 2017 and (iii) 1/3 of its shares as of January 2, 2018, in each case subject to the terms and provisions of a solvency letter described in the acquisition agreement. Additionally, the seller was granted a put option to sell and transfer all (but not part) of its shares, on (but not prior to) the date that is six months from the closing of the Agriphar Acquisition, which option was not exercised. As a result, for the period ended March 31, 2015, the value of the option totaling $3.0 million was reversed and included in "Other income (expense), net" in the Condensed Consolidated Statement of Operations. We acquired Agriphar in our crop protection vertical as we believe Agriphar’s and CAS’ businesses are very complementary in terms of product range and distribution capabilities. Agriphar is a European crop protection group supported by a team of researchers and regulatory experts which provides a wide range of fungicides, herbicides and insecticides with end markets primarily across Europe. Agriphar is included in the Company's Agricultural Solutions business segment. In connection with the Agriphar Acquisition, the Company incurred $0.3 million and $0.8 million in related expenses for the three and six months ended June 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $4.2 million in related expenses through December 31, 2014. Acquisition Revenues and Net Income (Loss) Revenues contributed by the Arysta, CAS and Agriphar Acquisitions for the three and six months ended June 30, 2015 were as follows: (amounts in millions) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Arysta $ 341.9 $ 519.4 CAS 105.2 208.6 Agriphar 46.4 120.0 Total $ 493.5 $ 848.0 As the integration of the Arysta, CAS and Agriphar Acquisitions continues, discrete revenues reported by the businesses are being effected by the integration process. and are becoming less comparable to prior periods. Arysta, CAS and Agriphar Acquisitions had net (loss) income for the three and six months ended June 30, 2015 as follows: (amounts in millions) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Arysta $ (61.5 ) $ (65.8 ) CAS 0.9 (27.5 ) Agriphar 4.2 22.4 Total $ (56.4 ) $ (70.9 ) Purchase Price Allocation The following table summarizes the consideration transferred and transaction related costs incurred to acquire Arysta, CAS and Agriphar and the applicable amounts of identified assets acquired and liabilities assumed at the acquisition date: (amounts in millions) Arysta CAS Agriphar Consideration Cash, net $ 2,856.2 $ 983.1 $ 350.2 Equity Instruments 645.9 52.0 16.6 Derivative liability — — 3.5 Total Consideration 3,502.1 1,035.1 370.3 Transaction related costs 34.2 43.7 5.0 Identifiable Assets acquired and Liabilities Assumed Accounts receivable 675.5 154.2 60.1 Inventories 294.8 132.1 42.7 Other current assets 132.2 19.1 0.4 Property, plant and equipment 110.0 24.8 31.7 Identifiable intangible assets 1,639.0 534.0 183.0 Other assets 38.2 21.5 4.5 Current Liabilities (570.4 ) (69.7 ) (47.5 ) Non-current deferred tax liability (489.5 ) (26.7 ) (64.9 ) Other long term liabilities (74.2 ) (13.4 ) (9.0 ) Non-controlling interest (24.6 ) — — Total identifiable net assets 1,731.0 775.9 201.0 Goodwill 1,771.1 259.2 169.3 Total purchase price $ 3,502.1 $ 1,035.1 $ 370.3 The purchase accounting and purchase price allocation for the Arysta Acquisition has not been finalized as of the date of this filing pending finalization of fair values assigned to identifiable intangible assets and non-controlling interest, as well as accounts receivable, inventory and reserves related to legal matters and environmental exposure. The purchase price allocation was updated to reflect current estimated fair values at the acquisition date, with the excess of purchase price over the estimated fair value of the net assets acquired recorded as goodwill. Purchase accounting and purchase price allocation is complete for the Agriphar Acquisition, and substantially complete for the CAS Acquisition, with the exception of valuations related to the supply agreements with Chemtura, and the valuation of the Certis Europe B.V. investment. As a part of the CAS Acquisition, the Company paid for a 15% equity interest in Certis Europe B.V. that was transferred during the second quarter of 2015 after receiving approval from the shareholders of Certis Europe B.V., who had certain rights of first refusal with respect to such transfer of shares. The value of the equity interest is estimated at $15.0 million based on market multiples and is classified in other assets. The excess of the respective cost of the Acquisitions over the net of amounts assigned to the fair values of the assets acquired and the liabilities assumed is recorded as goodwill and represents the value of estimated synergies and the assembled workforces resulting from the Acquisitions. Of the $2.20 billion of goodwill recorded in connection with the Arysta, CAS and Agriphar Acquisitions, $185 million is expected to be deductible for tax purposes as result of the CAS Acquisition. Identifiable intangible assets recorded in conjunction with the Arysta Acquisition have been assigned the following estimated useful lives: 20 years for customer lists, average of 12 years for developed technology and indefinite for tradenames. Pro Forma Revenue and Earnings The following unaudited pro forma summary presents consolidated information of the Company for the three and six months ended June 30, 2015 and 2014 , as if the Arysta Acquisition had occurred on January 1, 2014: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Revenue $ 675.1 $ 591.5 $ 1,297.4 $ 1,080.6 Net income (loss) attributable to stockholders $ 4.4 $ (34.4 ) $ (41.5 ) $ (112.0 ) For the three and six months ended June 30, 2015 , the Company incurred $4.9 million and $27.8 million , respectively, of acquisition-related expenses which have been reflected in the pro forma earnings above, net of tax, as if they had been incurred in 2014. These pro forma amounts have been prepared to reflect fair value adjustments to intangible assets and the related amortization expense, net of tax, from January 1, 2014, as well as the effect of the debt instruments used to fund the Arysta Acquisition. The pro forma summary presented above excludes CAS and Agriphar from the 2014 results as the acquisitions closed in the fourth quarter of 2014. Proposed OMG Acquisition On May 31, 2015, the Company entered into a merger agreement with OMG and affiliates of Apollo Global Management, LLC (collectively and each individually referred to herein as “Apollo”) and a purchase and separation agreement with Apollo pursuant to which Apollo will first acquire OMG in its entirety, and then subsequently sell to Platform the OMG Businesses. The OMG Acquisition will take place in two stages: the Company expects to first acquire all of the OMG Businesses, other than its Malaysian subsidiary, immediately after Apollo’s acquisition of OMG, currently expected to occur during the fourth quarter of 2015, and then subsequently to acquire the Malaysian subsidiary during the first quarter of 2016. The total purchase price, subject to purchase price adjustments, is approximately $367 million . Apollo’s acquisition of OMG is subject to certain customary closing conditions, including approval of the acquisition by the OMG's stockholders, expiration or termination of any applicable waiting periods under the HSRA Act, and other consents and approvals required under applicable U.S. and foreign antitrust laws. The first stage of the OMG Acquisition is subject only to the consummation of Apollo’s acquisition of OMG, and the second stage of the transaction is subject to additional standard closing conditions, including the absence of a material adverse effect with respect to the Malaysian subsidiary. On August 10, 2015, OMG's shareholders approved the proposed acquisition. If the merger agreement is terminated due to Platform's or Apollo’s failure to obtain financing for their respective transactions (and under certain other limited circumstances), (i) the Company and Apollo will be required to pay OMG a pro rata portion of a reverse termination fee to OMG equal to $62.7 million (and the party responsible for such termination of the merger agreement will be required to reimburse the other party for its or their pro rata portion of the amount paid to OMG) and (ii) the party responsible for such termination of the merger agreement will be required to reimburse the other party for its fees and expenses up to $7.5 million . If the merger agreement is terminated due to the failure to obtain certain regulatory approvals for the OMG Acquisition, the Company may be required to reimburse OMG for its fees and expenses up to $7.5 million , and to pay to Apollo its fees and expenses up to $7.5 million . ` Platform believes the proposed OMG Acquisition is in line with its business strategy of growing into niche markets and will be included in the Company's Performance Applications business segment. OMG’s Electronic Chemicals business is similar to Platform's legacy MacDermid electronic chemical and surface treatment businesses. It develops, produces and supplies chemicals for electronic and industrial applications. OMG’s Photomasks products are used by customers to produce semiconductors and related products.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventories	INVENTORIES The major components of inventory were as follows: (amounts in millions) June 30, December 31, 2014 Finished goods $ 326.8 $ 156.3 Work in process 16.0 — Raw materials and supplies 127.2 49.5 Total inventory, net $ 470.0 $ 205.8 In connection with the Arysta Acquisition, the fair value assessment of inventory resulted in an increase to finished goods of $39.0 million , of w hich $20.6 million and $36.5 million was charged to cost of sales during the three and six months ended June 30, 2015 , respectively, in the Condensed Consolidated Statement of Operations. The CAS inventory step-up became fully amortized during the three months ended March 31, 2015. For the six months ended June 30, 2015 , $20.2 million was charged to cost of sales in the Condensed Consolidated Statement of Operations in connection with the CAS Acquisition. The MacDermid inventory step-up became fully amortized during the three months ended March 31, 2014. For the six months ended June 30, 2014 , $12.0 million was charged to cost of sales in the Condensed Consolidated Statement of Operations in connection with the MacDermid Acquisition.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT AND EQUIPMENT The major components of property, plant and equipment, including equipment under capital leases, were as follows: (amounts in millions) June 30, December 31, 2014 Land and leasehold improvements $ 42.1 $ 36.6 Buildings and improvements 77.8 44.4 Machinery, equipment, fixtures and software 166.5 99.0 Assets under capital leases 21.7 8.9 308.1 188.9 Less: accumulated depreciation (41.9 ) (18.1 ) 266.2 170.8 Construction in process 14.4 4.2 Property, plant and equipment, net $ 280.6 $ 175.0 For the three months ended June 30, 2015 and 2014 , the Company recorded a depreciation expense of $13.4 million and $5.4 million , respectively. For the six months ended June 30, 2015 and 2014 , the Company recorded a depreciation expense of $21.5 million and $9.0 million , respectively. The net book value of assets acquired under capital leases was $16.0 million and $5.5 million at June 30, 2015 and December 31, 2014 , respectively. As of June 30, 2015, the Company designated Performance Application's San Marcos, CA facility, with a book value of $10.9 million , as an asset held-for-sale, in accordance with a restructuring plan to streamline the newspaper printing plate operations. The book value of the facility was reclassified from "Property, plant and equipment (net)" to "Prepaid expenses and other current assets" in the Condensed Consolidated Balance Sheet as of June 30, 2015. As of June 30, 2015, the Company also recorded a purchase accounting adjustment related to leased capital equipment acquired in connection with the CAS Acquisition totaling $13.2 million .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill by segment were as follows: (amounts in millions) Performance Applications Agricultural Solutions Total December 31, 2014 $ 961.2 $ 444.1 $ 1,405.3 Addition from acquisitions — 1,697.1 1,697.1 Purchase accounting adjustments — 43.8 43.8 Foreign currency translation (23.9 ) (109.5 ) (133.4 ) June 30, 2015 $ 937.3 $ 2,075.5 $ 3,012.8 The carrying value of indefinite-lived intangible assets other than goodwill, which consist solely of tradenames, was $238 million and $69.3 million at June 30, 2015 and December 31, 2014 , respectively. During the second quarter of 2015, as a result of a decline of forecasted cash flows, the Company performed an impairment analysis of the $73.2 million of goodwill assigned to the ASF Americas reporting unit. In performing the impairment test, the Company estimated the fair value of ASF Americas pursuant to an income approach based upon discounted cash flows. For the estimate of fair value, the Company estimated annual revenue growth rates for the initial five year forecast period to range from 4.2% to 5.6% and estimated a long term growth rate in determining the terminal value of the reporting unit of 3.0% . The discount rate for the estimate of fair value was based on a Weighted Average Cost of Capital, or WACC. The WACC combines the required return on equity, based on a Modified Capital Asset Pricing Model, which considers the risk-free interest rate, market risk premium, beta, small stock risk premium and a company specific risk premium, with the cost of debt, based on BBB rated corporate bonds, adjusted using an income tax factor. The calculation resulted in a WACC rate of 10.0% . The estimated fair value of ASF Americas exceeded its carrying value by 11.8% . As a result, there was no impairment of goodwill assigned to ASF Americas. Intangible assets subject to amortization were as follows: June 30, 2015 December 31, 2014 (amounts in millions) Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Customer lists $ 946.8 $ (104.5 ) $ 842.3 $ 613.6 $ (71.6 ) $ 542.0 Developed technology 1,855.5 (177.0 ) 1,678.5 760.5 (50.8 ) 709.7 Tradenames 19.0 (2.2 ) 16.8 19.7 (1.0 ) 18.7 Non-compete agreements 1.9 (0.3 ) 1.6 1.9 (0.1 ) 1.8 Total $ 2,823.2 $ (284.0 ) $ 2,539.2 $ 1,395.7 $ (123.5 ) $ 1,272.2 Useful lives range from 8 to 30 years for customer lists, 5 to 14 years for developed technology, 5 to 20 years for tradenames and 5 years for non-compete agreements, which results in weighted average useful lives of 20 years, 12 years, 20 years and 5 years, respectively, for an aggregate weighted average useful life of approximately 15 years at June 30, 2015 . For the three months ended June 30, 2015 and 2014 , the Company recorded amortization expense on intangible assets of $52.4 million and $16.0 million , respectively. For the six months ended June 30, 2015 , and 2014 , the Company recorded amortization expense on intangible assets of $92.2 million and $29.3 million , respectively. Annual amortization expense on the Company's intangible assets is estimated to total $198 million in 2015, $211 million in each of the years 2016 through 2019 , and $210 million in 2020 .

Equity Compensation Plans

Equity Compensation Plans	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Compensation Plans	EQUITY COMPENSATION PLANS In June 2014, the Company’s stockholders approved the 2013 Plan. The 2013 Plan is administered by the compensation committee; provided, however, that except as otherwise expressly provided in the 2013 Plan, the Board may exercise any power or authority granted to the compensation committee under the 2013 Plan. As of June 30, 2015 , the total number of shares of common stock that may be subject to the granting of awards under the 2013 Plan based on the grants issued (as discussed below) is equal to 15,500,000 shares (subject to increase in accordance with the terms of the 2013 Plan). As of June 30, 2015 , a total of 84,242 shares of common stock had been issued under the 2013 Plan. Six Months Ended June 30, 2015 Total RSUs Stock Options Equity Classified Liability Classified December 31, 2014 721,933 142,110 329,823 250,000 Granted 464,024 250,622 213,402 — Exercised (75,000 ) — — (75,000 ) Forfeited (25,984 ) (25,984 ) — — June 30, 2015 1,084,973 366,748 543,225 175,000 Equity Classified Share Based Payments During the six months ended June 30, 2015 , the Board approved grants totaling of 242,980 RSUs to certain employees of the Company under the 2013 Plan, with grant-date fair values ranging from $26.17 to $27.05 per unit and vesting periods ranging from 36 months to 57.5 months. In addition, 242,980 RSUs are subject to performance conditions that must be achieved in the final vesting year. During the six months ended June 30, 2015 , 25,984 RSU's were forfeited. On March 17, 2015, the Board approved grants to certain directors of Platform totaling 7,642 RSUs, effective March 25, 2015, with a grant-date fair value of $27.05 . The RSUs will vest on March 17, 2016, provided that such directors continue to serve as directors of Platform through the vesting date. Each RSU represents a contingent right to receive one share of our common stock. For the three months ended June 30, 2015 and 2014 , total compensation expense associated with these RSUs totaled zero and $0.3 million , respectively. For the six months ended June 30, 2015 and 2014 , total compensation expense associated with all RSUs totaled $0.3 million and $0.3 million , respectively. Liability Classified Share Based Payments On March 6, 2014, the Board approved a grant of 329,823 RSUs, effective on June 12, 2014 with approval of the 2013 Plan, to certain employees that cliff vest on December 31, 2020. The RSUs are subject to an EBITDA performance condition and a share price market condition. Additionally, the number of shares of common stock to be issued is limited to a maximum cash value, requiring these awards to be classified as liabilities. The combined undiscounted maximum cash value of all RSUs issued is approximately $7.1 million which is being recognized as compensation expense over the period from grant to the vesting date. During the six months ended June 30, 2015 , the Board approved a grant of 213,402 RSUs with a grant-date fair value of $23.43 per unit that cliff vest at the end of a 24 month period, and are subject to certain performance conditions. The awards have been classified as liabilities. The undiscounted maximum cash value of all RSUs issued is approximately $5.0 million which is being recognized as compensation expense over the period from grant to the vesting date. For the three months ended June 30, 2015 and 2014 , compensation expense associated with these awards totaled $0.9 million and $0.1 million , respectively. For the six months ended June 30, 2015 and 2014 , compensation expense associated with these awards totaled $1.4 million and $0.1 million , respectively. Stock Options On April 23, 2013, a former non-founder director was granted a five -year option to acquire 75,000 ordinary shares. This option was fully vested and, upon our Domestication, became an option to acquire shares of our common stock. On March 16, 2015, the option was exercised and 75,000 shares of our common stock were issued on March 19, 2015. Long Term Cash Bonus Plan During the three months ended March 31, 2015, the Company established the LTCB. As of June 30, 2015 , the plan provides participants the right to receive bonuses totaling $46.5 million upon completion of vesting periods ranging from 24.5 to 60 months. Approximately $12.5 million of the LTCB is subject to achieving a certain stock price target of Platform's common stock on the NYSE, subject to appropriate and equitable adjustments by the Board's compensation committee in the event Platform’s common stock is no longer publicly traded. The balance of the LTCB is subject to EBITDA performance targets that must be achieved, subject to appropriate and equitable adjustments by the Board's compensation committee to reflect any subsequent acquisition, divestiture or other corporate reorganizations. For the three and six months ended June 30, 2015 , compensation (income) expense associated with the LTCB totaled $(0.3) million and $0.8 million , respectively. Employee Stock Purchase Plan Effective March 6, 2014, the Board adopted the ESPP, which was approved by the Company’s stockholders on June 12, 2014. The Board approved a maximum of 5,178,815 shares of common stock, which were reserved and made available for issuance under the ESPP. As of June 30, 2015 , a total of 25,966 shares had been issued under the ESPP, and 573 persons were eligible to participate in the ESPP.

Pension, Post-Retirement and Po

Pension, Post-Retirement and Post-Employment Plans	6 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Pension, Post-retirement and Pose-Employment Plans	PENSION AND POST-RETIREMENT PLANS The components of net periodic pension and post-retirement benefit costs for the three and six months ended June 30, 2015 and 2014 were as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Pension & SERP Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic (benefit) cost: Service cost $ — $ 0.2 $ — $ 0.2 $ — $ 0.4 $ — $ 0.4 Interest cost on the projected benefit obligation 1.6 0.5 1.7 0.8 3.2 1.0 3.4 1.6 Expected return on plan assets (2.4 ) (0.5 ) (2.4 ) (0.9 ) (4.8 ) (1.0 ) (4.8 ) (1.8 ) Net periodic (benefit) cost $ (0.8 ) $ 0.2 $ (0.7 ) $ 0.1 $ (1.6 ) $ 0.4 $ (1.4 ) $ 0.2 Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Post-retirement Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic cost: Interest cost on the projected benefit obligation $ 0.1 $ — $ 0.1 $ — $ 0.2 $ — $ 0.2 $ — Net periodic cost $ 0.1 $ — $ 0.1 $ — $ 0.2 $ — $ 0.2 $ — No pension service cost was recognized during the three and six months ended June 30, 2015 and 2014 under the Domestic Pension Plan, nor will be in future periods, as benefits in the plan were frozen in connection with the MacDermid Acquisition.

Debt, Capital Leases, Financial

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt, Financial Guarantees And Factoring Arrangements	DEBT, CAPITAL LEASES, FINANCIAL GUARANTEES AND FACTORING ARRANGEMENTS The Company’s debt and capital lease obligations consisted of the following: (amounts in millions) June 30, December 31, 2014 Borrowings under lines of credit, $ 22.4 $ — USD Notes, due 2022, 1,079.5 — EUR Notes, due 2023, 383.4 — First lien secured credit facility and term loan, due 2020, 739.3 743.0 USD Incremental Loan, due 2020, 291.7 292.7 New Tranche B Term Loan, due 2020, 121.9 121.7 New Tranche B-2 Term Loan, due 2020, 482.1 — Euro Tranche Term Loan, due 2020, 225.7 246.2 New Euro Tranche Term Loan, due 2020, 90.3 — Capital lease obligations 4.5 2.0 Total debt and capital lease obligations 3,418.4 1,405.6 Less: current portion debt and capital lease obligations (16.8 ) (13.2 ) Total long-term debt and capital lease obligations $ 3,401.6 $ 1,392.4 The Company adopted ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs” as of June 30, 2015, and reclassified approximately $48.6 million and $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of June 30, 2015 and December 31, 2014, respectively, of which $4.7 million and $1.9 million , respectively, was classified as current. Minimum principal payments on long-term debt and capital leases were as follows: (amounts in millions) Principal Payments Year ending December 31, 2015 - remaining $ 10.9 2016 20.8 2017 20.5 2018 20.4 2019 20.4 2020 1,892.6 Thereafter 1,492.1 Total $ 3,477.7 Second Amended and Restated Credit Agreement On August 6, 2014, the Company amended and restated its senior secured credit facilities by entering into Amendment No. 2 to the First Lien Credit Facility and the Second Amended and Restated Credit Agreement, and agreeing on the implementation of certain Further Amendments to the Second Amended and Restated Credit Agreement. Upon consummation of the CAS Acquisition on November 3, 2014, the Further Amendments became effective, increasing (i) the existing U.S. Dollar revolving credit facility to $87.5 million and (ii) the existing multicurrency revolving credit facility to $87.5 million . On the date of the CAS Acquisition, the Company also borrowed (i) an aggregate principal amount of $130 million under the New Tranche B Term Loan, (ii) $60.0 million under the U.S. Dollar Revolving Credit Facility, and (iii) €55.0 million under the multicurrency Revolving Credit Facility. The amounts under (ii) and (iii) in the immediately preceding sentence were both settled by December 31, 2014. In addition, an aggregate amount of €205 million was borrowed under the Euro Tranche Term Loan by MAS Holdings and NAIP, subsidiaries of Platform. Pursuant to the Further Amendments, certain additional domestic and foreign subsidiaries of Platform and MacDermid became guarantors under the Amended and Restated Credit Agreement, and certain additional collateral was pledged to secure the Company's obligations incurred under the Euro Tranche Term Loan and the other loans incurred under the Revolving Credit Facility. With the exception of this collateral package and the interest rate, the Euro Tranche Term Loan has terms substantially similar to those of Platform’s New Tranche B Term Loan and bears interest at a rate per annum equal to an applicable margin plus an adjusted Eurocurrency Rate, calculated as set forth in the Amended and Restated Credit Agreement. The Euro Tranche Term Loan matures on June 7, 2020. On October 1, 2014, Platform and MacDermid, as borrowers, MacDermid Holdings, certain subsidiaries of MacDermid Holdings and Platform, and Barclays Bank PLC, as collateral and administrative agent and incremental lender, entered into the Incremental Amendment to the Amended and Restated Credit Agreement for an USD Incremental Loan in an aggregate principal amount of $300 million . Except as set forth in the Incremental Amendment, such USD Incremental Loan has identical terms as the existing Tranche B term loans and is otherwise subject to the provisions of the Amended and Restated Credit Agreement. The proceeds from the Incremental Amendment were used to finance the Agriphar Acquisition. On February 13, 2015, the Company entered into and closed the transactions contemplated by Amendment No. 3 to the Second Amended and Restated Credit Agreement, which, among other things, provided for (i) a New Tranche B-2 of Term Loan denominated in U.S. dollars in an aggregate principal amount of $500 million , (ii) an increase in the size of the existing Euro Tranche Term Loan by €83.0 million to €287 million , (iii) an increase in the size of the existing U.S. Dollar Revolving Credit Facility by $75.0 million to $163 million , and (iv) an increase in the size of the existing multicurrency Revolving Credit Facility by $75.0 million to $163 million . Concurrently with the closing of the Arysta Acquisition, the Company borrowed (i) a New Tranche B-2 Term Loan of $500 million (less original issue discount of 1% ), (ii) an additional New Euro Tranche Term Loan of €83.0 million (less original issue discount of 2% ), and (iii) $160 million under the U.S. Dollar Revolving Credit Facility to fund a portion of the cash consideration for the Arysta Acquisition. Certain additional domestic and foreign subsidiaries of Platform and MacDermid, including certain subsidiaries acquired in the Arysta Acquisition, have since become guarantors under the Amended and Restated Credit Agreement, with certain of the Company's subsidiaries having pledged collateral in connection therewith. The New Tranche B-2 Term Loan bears interest at a rate per annum equal to 3.75% plus an adjusted Eurocurrency rate, or 2.75% plus an adjusted base rate, calculated as set forth in the Amended and Restated Credit Agreement, and matures on June 7, 2020. Pursuant to Amendment No. 3, the previously existing New Tranche B Term Loan now bears interest at 3.50% per annum plus an adjusted Euro currency rate, or 2.50% plus an adjusted base rate, calculated as set forth in the Amended and Restated Credit Agreement. Revolving loans under the Amended and Restated Credit Agreement bear interest at a rate per annum equal to 3.00% plus an adjusted Eurocurrency rate, or 2.00% plus an adjusted base rate, each as calculated as set forth in the Amended and Restated Credit Agreement, and mature on June 7, 2018. Except as set forth in Amendment No. 3 and above, the New Tranche B-2 Term Loan has identical terms as the existing New Tranche B Term Loan and is otherwise subject to the provisions of the Amended and Restated Credit Agreement. Covenants and Events of Default The Amended and Restated Credit Agreement contains customary covenants including limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, use of loan proceeds, capital expenditures, restricted payments, restrictions on liens, transactions with affiliates, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. Amendment No. 3, among other things, provides additional flexibility with respect to certain negative covenants, including by increasing certain dollar baskets as compared to the previous amendments. The Revolving Credit Facility also imposes a financial covenant, if borrowings under the Revolving Credit Facility and letter of credit obligations exceed 25% of the revolving credit commitments as of the last day of any fiscal quarter, which limits Platform to a 6.5 to 1.0 ratio of (x) consolidated indebtedness secured by a first lien minus unrestricted cash and cash equivalents of the borrowers and guarantors under the Amended and Restated Credit Agreement to (y) consolidated EBITDA for the four most recent fiscal quarters, subject to a right to cure. As of June 30, 2015 , the Company was in compliance with the debt covenants contained in its Credit Facilities. The Amended and Restated Credit Agreement also contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of certain covenants, inaccuracy of representations and warranties, failure to make payment on certain other material indebtedness, bankruptcy and insolvency events, material judgments and change of control provisions. Upon the occurrence of an event of default, payment of any outstanding loans under the Amended and Restated Credit Agreement may be accelerated. Borrowings under the Amended and Restated Credit Agreement are also subject to mandatory prepayment from the proceeds of certain dispositions of assets and from certain insurance and condemnation proceeds, excess cash flow and debt incurrences, in each case, subject to customary carve-outs and exceptions. Guarantees The obligations of Platform and MacDermid, as borrowers, under the Amended and Restated Credit Agreement are guaranteed by ocurrent and future direct and indirect domestic subsidiaries. Certain of Platform's foreign subsidiaries also guarantee the obligations of MAS Holdings and NAIP with respect to the Euro Tranche Term Loan and the New Euro Tranche Term Loan. Pursuant to the Security Agreement, the Company's obligations under the Amended and Restated Credit Agreement are secured by a security interest in substantially all of the personal property, whether owned on the date the Security Agreement, or entered into or acquired in the future, of Platform and MacDermid, as borrowers, and the guarantors listed in the Security Agreement, including the pledge by Platform, MacDermid and guarantors generally of 100% of the voting common stock and other equity interests in all of their respective domestic subsidiaries and 65% of the voting common stock and other equity interests in all of their respective directly owned non-domestic subsidiaries (in each case, whether existing on the date the Security Agreement or entered into or acquired thereafter), subject to certain exceptions contained in the Amended and Restated Credit Agreement and the Security Agreement. Notes Offering In connection with the Arysta Acquisition, on February 2, 2015, the Platform completed the private offering of $1.10 billion aggregate principal amount of 6.50% USD Notes due 2022, and €350 million aggregate principal amount of 6.00% EUR Notes due 2023, plus original issue premium of $1.0 million . The Notes are governed by an indenture, dated February 2, 2015, as amended by a first supplemental indenture dated February 13, 2015 and a second supplemental indenture dated May 20, 2015. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 mature on February 1, 2022 and February 1, 2023, respectively, unless earlier redeemed. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 bear interest at a rate of 6.50% and 6.00% per year, respectively, until maturity. Interest is payable in cash, semi-annually in arrears, on February 1 and August 1 of each year, beginning on August 1, 2015. Platform will make each interest payment to the holders of record to be determined on the immediately preceding January 15 and July 15. The notes are (i) Platform’s senior unsecured obligations, ranking equally in right of payment with all of Platform’s existing and future senior unsecured debt and ranking senior in right of payment to all of Platform’s existing and future unsecured subordinated debt; (ii) effectively subordinated to Platform’s secured indebtedness, including the debt outstanding under the Amended and Restated Credit Agreement, to the extent of the value of the assets securing such debt, and are structurally subordinated to indebtedness and other liabilities, including trade payables, of Platform’s non-guarantor subsidiaries; and (iii) jointly and severally, fully and unconditionally guaranteed on a senior unsecured basis generally by current and future direct and indirect domestic subsidiaries that guarantee the Amended and Restated Credit Agreement. Lines of Credit and Other Debt Facilities The Company carries various lines of credit, short-term debt facilities and overdraft facilities worldwide which are used to fund short-term cash needs. As of June 30, 2015 , borrowings under such facilities totaled $22.4 million . At December 31, 2014 , there were no borrowings under such facilities. The Company also had letters of credit outstanding of $7.3 million and $1.0 million at June 30, 2015 and December 31, 2014 , respectively, which reduce the borrowings available under the various credit facilities. At June 30, 2015 and December 31, 2014 , the availability under these facilities was approximately $367 million and $195 million , respectively, net of outstanding letters of credit. As of June 30, 2015 , interest rates on such facilities ranged from 0.45% to 25.00% . Financial Guarantees and Factoring Arrangements The Company periodically enters into certain arrangements with vendors and customers under which it provides guarantees to financial institutions for loans entered into between its vendors and customers and the financial institutions, the proceeds of which are used to settle outstanding accounts receivables. The terms of the guarantees are equivalent to the terms of the customer loans. Liabilities for the guarantees are recorded at amounts that approximate fair value, based on the Company’s historical collection experience with vendors and customers that participate in the program and a current assessment of credit exposure. Such liabilities are included in "Financial guarantees and factoring" in the Company's Condensed Consolidated Balance Sheet, and totaled $23.5 million and zero as of June 30, 2015 and December 31, 2014 , respectively. Program income and expenses are recorded in "Interest expense, net" in the Condensed Consolidated Statement of Operations and totaled zero for the three months ended June 30, 2015 and 2014 . For the six months ended June 30, 2015 and 2014 , the Company recorded program expenses of $0.2 million and zero , respectively. The Company also utilizes accounts receivable factoring arrangements as a part of its working capital management strategies. Total current capacity under such programs is approximately $244 million as of June 30, 2015 . Under these arrangements, factored accounts receivable may be transferred with or without recourse. Factoring transactions qualifying for sales treatment, whereas the derecognition criteria have been met, totaled $90.6 million and zero as of June 30, 2015 and December 31, 2014 , respectively. Account receivable balances related to arrangements not having met the derecognition criteria, whereas the risks and rewards of ownership have not been transferred, remain recorded in "Account receivable" and the related liabilities are included in "Financial guarantees and factoring" in the Company's Condensed Consolidated Balance Sheet, and totaled $46.5 million and zero as of June 30, 2015 and December 31, 2014 , respectively. Factoring fees are recorded in "Interest expense, net" in the Condensed Consolidated Statement of Operations and totaled $0.5 million and zero for the three months ended June 30, 2015 and 2014 , respectively. For the six months ended June 30, 2015 and 2014 , the Company recorded factoring fees of $1.2 million and zero , respectively.

Derivative Instruments

Derivative Instruments	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS In the normal course of business, the Company is exposed to risks relating to changes in foreign currency exchange rates, interest rates and commodity prices. Derivative financial instruments, such as foreign currency exchange rate instruments, are used to manage changes in market conditions related to foreign currency exchange rate volatility. All derivatives are recognized on the Condensed Consolidated Balance Sheets at fair value at the end of each period. The counterparties to the Company’s derivative agreements are major international financial institutions. The Company continually monitors its positions and the credit ratings of its counterparties and does not anticipate nonperformance by the counterparties. Foreign Currency The Company conducts a significant portion of its business in currencies other than the U.S. dollar, the currency in which the Condensed Consolidated Financial Statements are reported, and as a result, the Company’s operating results are affected by foreign currency exchange rate volatility relative to the U.S. dollar. As of June 30, 2015 , the aggregate U.S. dollar notional amount of foreign currency forward contracts, none of which were designated as hedges, totaled $139 million , all with settlement dates within one year. The majority of forward contracts are in U.S. dollars ( $125 million ), British pounds ( £5.9 million ) and Euros ( €4.2 million ), with lesser amounts in Chinese yuans and Australian dollars. The market value of forward contracts are determined using pricing models based upon observable market inputs including both forward and spot prices for the underlying currencies. The net fair value of the foreign currency forward contracts is recorded as an unrealized gain (loss) under "Other (expense) income, net" in the accompanying Condensed Consolidated Statement of Operations. The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets: (amounts in millions) June 30, December 31, 2014 U.S. Dollar Amount U.S. Dollar Amount Derivatives not designated as hedging instruments: Assets Balance Sheet Location Foreign exchange contracts Prepaid expenses & other current assets $ 0.7 $ — Liabilities Balance Sheet Location Foreign exchange contracts Other current liabilities — 0.1 Total derivative contracts $ 0.7 $ (0.1 ) During the three and six months ended June 30, 2015 , there were no unrealized gains (losses) recorded in Other Comprehensive Income related to foreign currency hedges. During the three and six months ended June 30, 2014 , unrealized losses recorded in Other Comprehensive Income totaled $0.2 million . During the three and six months ended June 30, 2015 , the Company recorded $1.4 million of realized losses in "Other (expense) income, net" related to the settlement of hedged foreign exchange contracts. During the three and six months ended June 30, 2014 , realized gains recorded in "Other (expense) income, net" totaled $0.3 million and $0.5 million , respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company has used the most advantageous market, which is the market in which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: • Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model derived valuations whose inputs are observable or whose significant valuation drivers are observable. • Level 3 – significant inputs to the valuation model are unobservable and/or reflect the Company’s market assumptions. Recurring Fair Value Measurements The following tables present the Company’s financial instruments, assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurement Using (amounts in millions) June 30, Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 29.2 $ 29.2 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Derivatives 0.7 — 0.7 — Total $ 32.2 $ 30.7 $ 1.5 $ — Liability Category Long term contingent consideration $ 67.5 $ — $ — $ 67.5 Total $ 67.5 $ — $ — $ 67.5 Fair Value Measurement Using (amounts in millions) December 31, 2014 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 15.4 $ 15.4 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Total $ 17.7 $ 16.9 $ 0.8 $ — Liability Category Long term contingent consideration $ 63.9 $ — $ — $ 63.9 Derivatives 0.1 — 0.1 — Total $ 64.0 $ — $ 0.1 $ 63.9 Money market accounts are included in "Cash and cash equivalents" in the Condensed Consolidated Balance Sheets. Available for sale equity securities are included in "Other assets" in the Condensed Consolidated Balance Sheets. The following methods and assumptions were used to estimate the fair value of each class of the Company’s financial instruments, assets and liabilities: Money market accounts - The Company invests in various money market funds which are managed by financial institutions. These money market funds are not publicly traded, but historically have been highly liquid. The fair value of the money market accounts is determined by the banks based upon the funds’ net asset values, or NAV. All of the money market accounts currently permit daily investments and redemptions at $1.00 NAV. Available for sale equity securities - Equity securities classified as available for sale are measured using quoted market prices at the reporting date multiplied by the quantity held. Level 2 equity securities are measured using quoted prices for similar instruments in active markets. Derivatives - The fair values of foreign currency derivatives were determined using pricing models based upon observable market inputs including both forward and spot prices for the underlying currencies. Long term contingent consideration - The long term contingent consideration represents a potential liability of up to $100 million tied to achievement of EBITDA and common stock trading price performance metric over a seven -year period ending December 2020 in connection with the MacDermid Acquisition. The common stock performance metric has been satisfied. The fair value of the EBITDA performance metric is derived using the income approach with unobservable inputs, based on future forecasts and present value assumptions which include a discount rate of approximately 1.8% and expected future value of payments of $60.0 million calculated using a probability weighted EBITDA assessment with higher probability associated with the Company achieving the maximum EBITDA targets. For the three and six month ended June 30, 2015 , the fair value of the long term contingent consideration increased by $0.9 million and $3.6 million , respectively. For the three and six month ended June 30, 2014 , the fair value of the long term contingent consideration increased by $10.8 million and $23.8 million , respectively. Changes in the fair value of the long term contingent consideration is recorded in "Selling, technical, general and administrative expenses" in the Condensed Consolidated Statement of Operations. An increase or decrease in the discount rate of 0.5% changes the fair value measure of each component by $1.0 million . As of June 30, 2015 and 2014 , there were no significant transfers between the fair value hierarchy levels. Nonrecurring Fair Value Measurements The following table presents the carrying value and estimated fair value of the Company’s long term debt and capital lease obligations: (amounts in millions) June 30, 2015 December 31, 2014 Long term debt - including current portion Carrying Value Fair Value Carrying Value Fair Value USD Notes, due 2022, interest at 6.50% $ 1,079.5 $ 1,117.3 $ — $ — EUR Notes, due 2023, interest at 6.00% 383.4 384.3 — — First Lien Credit Facility 739.3 738.3 743.0 720.7 USD Incremental Loan 291.7 291.4 292.7 283.9 New Tranche B Term Loan 121.9 121.8 121.7 118.0 New Tranche B-2 Term Loan 482.1 481.5 — — Euro Tranche Term Loan 225.7 225.4 246.2 238.8 New Euro Tranche Term Loan 90.3 90.2 — — Capital lease obligations 4.5 4.5 2.0 2.6 Total $ 3,418.4 $ 3,454.7 $ 1,405.6 $ 1,364.0 The following methods and assumptions were used to estimate the fair value of the Company’s long term debt: Long-term Debt Instruments - These financial instruments are measured using quoted market prices at the reporting date multiplied by the carrying amount of the related debt. Such instruments are valued using Level 2 inputs.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY Underwritten Public Offering On June 23, 2015, we entered into an underwriting agreement with Credit Suisse Securities (USA) LLC and Barclays Capital Inc., as representatives of several underwriters relating to the June 2015 Equity Offering of 18,226,414 shares of our common stock at a public offering price of $26.50 per share. This number of shares includes 2,377,358 shares sold to the underwriters upon exercise in full of their option to purchase additional shares. The June 2015 Equity Offering was registered with the SEC pursuant to a Registration Statement on Form S-3, as amended (File Nos. 333-205010 and 333-205181), initially filed by Platform on June 17, 2015. The June 2015 Equity Offering closed on June 29, 2015 and resulted in gross proceeds to Platform of approximately $483 million , before underwriting discounts, commissions and offering expenses of $14.8 million . Preferred Stock Pursuant to the Company's Certificate of Incorporation, as amended, 5,000,000 shares of preferred stock are authorized. The Board has designated 2,000,000 shares as "Series A Preferred Stock." As of June 30, 2015 and December 31, 2014 , a total of 2,000,000 shares were issued and outstanding. The Board has also designated 600,000 shares as "Series B Convertible Preferred Stock," which are redeemable and are presented in the mezzanine section of the Company's Condensed Consolidated Balance Sheet. As of June 30, 2015 and December 31, 2014 , a total of 600,000 and zero shares, respectively, were issued and outstanding. Shares of preferred stock have no voting rights, except in respect of any amendment to the Company's Certificate of Incorporation, as amended, that would alter or change their rights or privileges. Series A Preferred Stock The Founder Entities are the current holders of our outstanding 2,000,000 shares of Series A Preferred Stock and are entitled to receive dividends on such Series A Preferred Stock in the form of shares of common stock. On December 31, 2014 , the Company approved a stock dividend of 10,050,290 shares of our common stock with respect to our outstanding Series A Preferred Stock. The dividend price was $22.85 , and the shares were issued on January 2, 2015 based on the volume weighted average price of $23.16 on December 31, 2014 . Each share of Series A Preferred Stock is convertible into one share of common stock at the option of the holders until December 31, 2020. Shares of Series A Preferred Stock will be automatically converted into shares of common stock on a one for one basis (i) in the event of a change of control of the Company following an acquisition or (ii) upon the last day of the seventh full financial year following the MacDermid Acquisition, being December 31, 2020 (extendable by our Board for three additional years). Series B Convertible Preferred Stock In connection with the Arysta Acquisition, the Company issued to the Seller 600,000 shares of Series B Convertible Preferred Stock, which have a $1,000 per share liquidation preference. The fair value of these shares, $646 million , was recognized as "Redeemable preferred stock – Series B" in the Condensed Consolidated Balance Sheet. At any time, the Seller may convert these shares into common stock of Platform at a conversion price of $27.14 . Additionally, any shares that have not been converted will be redeemed for the $1,000 per share liquidation preference in the event of (i) certain mergers or consolidations, (ii) the sale of substantially all the Company’s assets or subsidiaries or (iii) the liquidation of the Company. Further, any shares that are not converted or redeemed will mandatorily convert to shares of common stock of Platform on October 20, 2016 at the $27.14 conversion price. Upon such mandatory conversion, the Company will pay the Seller in cash any deficit between (i) the 10 -day volume weighted price of Platform’s common stock prior to such mandatory conversion and (ii) $27.14 per share. Such make whole payment may be reduced by the outcome of the arbitration matter described in Note 15 of the Condensed Consolidated Financial Statements. If such make whole payment is less than the amount resolved in connection with this arbitration matter, the deficit will be due from the Seller. In connection with the issuance of the Series B Convertible Preferred Stock, the Company entered into a registration rights agreement with the Seller dated February 17, 2015, pursuant to which it agreed to (i) file a registration statement with the SEC covering the resale of a maximum of 22,107,590 shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock, as soon as reasonably practicable following the issuance of the Series B Convertible Preferred Stock, and (ii) use its commercially reasonable efforts to cause the SEC to declare such registration statement effective by not later than six months following the date of the registration rights agreement. On February 25, 2015, the Company filed the Seller Resale Registration Statement to register the resale of a maximum of 22,107,590 shares of common stock. Such resale registration statement was amended on March 20, 2015 and April 29, 2015, and declared effective by the SEC on May 6, 2015. Option Exercise On April 23, 2013, a former non-founder director was granted a five -year option to acquire 75,000 ordinary shares. This option was fully vested and, upon our Domestication, became an option to acquire shares of our common stock. On March 16, 2015, the option was exercised and 75,000 shares of our common stock were issued on March 19, 2015. Non-Controlling Interest In connection with the MacDermid Acquisition, approximately $97.5 million was raised in new equity consisting of shares of PDH Common Stock that may be converted in shares of our common stock at a rate of 25% per year over a four-year period. The PDH Common Stock is classified as a non-controlling interest on the Condensed Consolidated Balance Sheets at June 30, 2015 and December 31, 2014 and will continue to be until such time as it is fully converted in shares of our common stock. The total number of shares of common stock originally issuable upon the exchange of PDH Common Stock pursuant to the RHSA was approximately 8.8 million , against which 561,577 shares have been issued as of June 30, 2015 . For the three months ended June 30, 2015 and 2014 , approximately $2.0 million and $1.8 million , respectively, of net (loss)income has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations, representing non-controlling interest of 6.36% and 6.76% at June 30, 2015 and 2014 , respectively. For the six months ended June 30, 2015 and 2014 , approximately $1.2 million and $3.1 million , respectively, of net income has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations. As a result of the Arysta Acquisition, approximately $24.6 million of non-controlling interest was recorded in purchase accounting as a result of the consolidation of less-than-wholly-owned subsidiaries.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME A summary of the changes in each component of accumulated other comprehensive (loss) income, net of tax for the three months and six months ended June 30, 2015 and 2014 were as follows: Three Months Ended June 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Loss Balance at March 31, 2015 $ (547.5 ) $ (15.4 ) $ — $ — $ 15.1 $ (547.8 ) Other comprehensive income (loss) before reclassifications, net 161.5 — 0.3 — (1.6 ) 160.2 Reclassifications, pretax — — — — — — Tax benefit reclassified — — — — — — Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Six Months Ended June 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2014 $ (122.2 ) $ (14.9 ) $ 0.1 $ — $ 6.4 $ (130.6 ) Other comprehensive (loss) income before reclassifications, net (263.8 ) — 0.2 — 7.1 (256.5 ) Reclassifications, pretax — — — — — — Tax benefit reclassified — (0.5 ) — — — (0.5 ) Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Three Months Ended June 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2014 $ 2.7 $ 2.0 $ — $ — $ — $ 4.7 Other comprehensive income before reclassifications, net 19.7 — 0.1 — (1.3 ) 18.5 Reclassifications, pretax — — (0.1 ) (0.1 ) — (0.2 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1 Six Months Ended June 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2013 $ (0.6 ) $ 1.8 $ — $ 0.1 $ — $ 1.3 Other comprehensive income before reclassifications, net 23.0 0.2 0.1 — (1.3 ) 22.0 Reclassifications, pretax — — (0.1 ) (0.2 ) — (0.3 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE A computation of the weighted average shares outstanding for the three and six months ended June 30, 2015 and 2014 follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions, except per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders $ (12.2 ) $ (0.4 ) $ (38.9 ) $ (7.8 ) Basic weighted average common stock outstanding 192.8 128.6 192.3 117.9 Convertible and performance-based stock (1) — — — — Dilutive weighted average common stock outstanding 192.8 128.6 192.3 117.9 Earnings per share attributable to common stockholders: Basic $ (0.06 ) $ — $ (0.20 ) $ (0.07 ) Diluted $ (0.06 ) $ — $ (0.20 ) $ (0.07 ) 1 No share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive. For more information about such dilutive shares outstanding, refer to the table below. For the three and six months ended June 30, 2015 and 2014 , the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because performance targets were not yet achieved for awards contingent upon performance. Three Months Ended June 30, Six Months Ended June 30, (amounts in thousands) 2015 2014 2015 2014 Number of shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock 2,789 11,279 2,789 11,279 Number of shares issuable upon conversion of warrants — — — 2,243 Number of shares issuable upon conversion of PDH Common Stock 8,213 8,775 8,213 8,775 Number of shares issuable upon conversion of Series A Preferred Stock 2,000 2,000 2,000 2,000 Number of shares issuable upon conversion of Series B Convertible Preferred Stock 22,108 — 16,733 — Number of shares contingently issuable for the contingent consideration 1,347 713 1,333 713 Number of shares issuable upon conversion of the 401k exchange rights — — — 544 Number of stock options 69 88 79 80 Number of restricted stock shares and units 161 2 89 1 36,687 22,857 31,236 25,635

Operating Lease Commitments

Operating Lease Commitments	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Operating Lease Commitments	OPERATING LEASE COMMITMENTS The Company leases certain land, office space, warehouse space and equipment under agreements which are classified as operating leases for financial statement purposes. Certain of these leases provide for payment of real estate taxes, common area maintenance, insurance and certain other expenses. Lease terms may have escalating rent provisions and rent holidays which are recognized on a straight-line basis over the term of the lease. The leases expire at various dates through 2047. Total rental expense for operating leases was as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Rent Expense $ 6.1 $ 2.5 $ 10.4 $ 5.0 Minimum non-cancelable operating lease commitments were as follows: (amounts in millions) Operating Lease Payment Year ending December 31, 2015, remaining $ 7.0 2016 9.5 2017 6.5 2018 4.8 2019 3.8 2020 3.1 Thereafter 12.8 $ 47.5 The fixed operating lease commitments detailed above assume that the Company continues the leases through their initial lease terms.

Contingencies, Environmental an

Contingencies, Environmental and Legal Matters	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies, Environmental and Legal Matters	CONTINGENCIES, ENVIRONMENTAL AND LEGAL MATTERS Asset Retirement Obligations The Company has recognized asset retirement obligations, or AROs, for properties where it can make a reasonable estimate of the future expenditures necessary to satisfy the related obligations. The Company considers identified legally enforceable obligations, estimated settlement dates and appropriate discount and inflation rates in calculating the fair value of its AROs. As of June 30, 2015 and December 31, 2014 , the Company's ARO reserves, included in other current and long term liabilities in the Condensed Consolidated Balance Sheets, totaled $17.7 million and $18.5 million , respectively, for sites in Europe, Latin America and North America. Changes in the Company’s AROs were as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 AROs, beginning of period $ 17.4 $ 4.9 $ 18.5 $ 4.8 Acquisitions 0.4 0.3 0.4 0.3 Accretion expense 0.2 0.2 0.5 0.3 Remeasurements (0.7 ) — (0.7 ) — Foreign currency adjustments 0.4 — (1.0 ) — AROs, end of period $ 17.7 $ 5.4 $ 17.7 $ 5.4 Environmental The Company formulates and distributes specialty chemical products, and is exposed to claims with respect to environmental cleanup or other matters, including those in connection with the disposal of hazardous materials. The Company is subject to extensive domestic and foreign laws and regulations relating to environmental protection and worker health and safety, including those governing discharges of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the cleanup of contaminated properties. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations. Additional costs could be incurred, including cleanup costs, fines, sanctions, and third-party claims, as a result of violations of or liabilities under environmental laws. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of potentially responsible parties. The Company has received notices of violation with respect to instances of non-compliance with environmental laws. A number of facilities and former facilities of the Company have been environmentally impacted from historic operations and some facilities are in the process of being investigated and remediated. As of June 30, 2015 and December 31, 2014 , approximately $2.1 million and $4.5 million , respectively, was reserved for various environmental matters. Ultimate costs may vary from current estimates. The discovery of additional contaminants at these facilities or other sites or the imposition of additional cleanup obligations or third-party claims relating thereto could result in additional costs. Management believes that any possible losses related to environmental remediation in addition to the amounts recorded as of June 30, 2015 and December 31, 2014 would not be material to the Company’s consolidated financial position, results of operations or cash flows. Legal Proceedings From time to time, the Company is involved in various legal proceedings in the normal course of its business. We believe that the resolution of these claims, to the extent not covered by insurance, will not individually or in the aggregate, have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. As of June 30, 2015 and December 31, 2014 , the Company has reserved approximately $5.9 million and $4.4 million , respectively, for its outstanding legal proceedings. The following is a description of certain litigation matters. Product liability and/or personal injury claims for, or relating to, products we sell under our Agricultural Solutions segment are complex in nature and have outcomes that are difficult to predict. Since these products are used in the food chain on a global basis, any such product liability or personal injury claim could lead to litigation in multiple jurisdictions. During 2014, Agricola Colonet, SA de CV claimed that certain Arysta products purchased from a retail distributor in Mexico were contaminated, requiring treated crops to be destroyed. Agricola Colonet, SA de CV is seeking compensation of approximately $11.3 million . The Company believes that it has adequate defenses and intends to vigorously defend against this claim, and therefore has not established a reserve related to this claim. Under its risk management policies, the Company maintains certain insurance policies under which such claims may be covered. In March 2013, a claim was filed against Arysta LifeScience Corporation, a subsidiary of the Company, relating to a purchasing optimization agreement entered into in 2011 between Arysta LifeScience Corporation and a consulting firm. The agreement provided for an incentive fee to be paid to the plaintiff based upon savings to Arysta resulting from the plaintiff's work. In addition to fees already received, the plaintiff claims damages, which the Company considers to be non-material. The Company believes this claim is without merit and that the fees already paid under the agreement exceed or equal the fees owed to the plaintiff. An arbitration hearing was conducted in May 2014, and in May 2015 the tribunal published a partial award, ruling on various issues of principle, but declining to calculate an award amount, rather asking the parties to attempt to agree upon a calculation reflecting the decisions of the tribunal set out in the award. The plaintiff subsequently filed for an application for clarification of the partial award, to which the Company responded by filing its own calculation of the award. The Company is currently awaiting further decisions from the tribunal. The $600 million of Series B Convertible Preferred Stock issued in connection with the Arysta Acquisition may be converted into a maximum of 22,107,590 shares of Platform common stock. To the extent that the aggregate value of such shares is less than $600 million (based on a 10 -day volume weighted average price), then, such shortfall would be payable in cash by Platform. Such shortfall would however be reduced by a portion, or all, of the amount for which the arbitration matter described in the preceding paragraph may be resolved, either by order of the arbitrators or by settlement, pursuant to a formula negotiated by and between the Company and the Seller. In June 2009, a lawsuit was filed by a private individual against Arysta LifeScience do Brasil Industria Química e Agropecuária Ltda, or Arysta Brazil, and 25 other defendants, and in November 2011, a claim was filed against Arysta Brazil and five other defendants by the city of Ulianopolis, in each case in connection with materials sent by Arysta Brazil and others to an incineration site owned and operated by an unaffiliated third party in the state of Pará, Brazil. Arysta Brazil was summoned and has filed its answer in connection with both cases. Proceedings have been suspended until October 15, 2015 in order to allow the Pará State Attorney to conduct civil inquiries to determine the extent of contamination and the appropriate remediation, and to identify potentially responsible parties. Damages sought in the private lawsuit include a penalty of BRL 50.0 million ( $16.1 million , based on the BRL/USD exchange rate of 0.3223 on June 30, 2015 ), plus interest and the cost of remediation. The cost of remediation in the case brought by the city of Ulianopolis was previously estimated by the city to be BRL 70.9 million ( $22.9 million , based on the BRL/USD exchange rate of 0.3223 on June 30, 2015 ). In addition, 13 former employees of the incineration facility have brought actions naming 80 defendants, including Arysta Brazil, seeking compensation in an aggregate amount of BRL 173.3 million ( $55.9 million , based on the BRL/USD exchange rate of 0.3223 on June 30, 2015 ) for health problems allegedly contracted as a result of their employment at the incineration site. In April 2014, Arysta LifeScience North America, LLC, or ALSNA, was served by Natividad and Francisco Sanchez, as plaintiffs, with a complaint naming over 30 defendants, including several chemical companies and crop protection companies. The complaint alleges that one of the plaintiffs was exposed to various products during the course of employment with various employers between 1989 and 2012, and that those products caused the plaintiff to develop medical conditions, including acute myelogenous leukemia. The plaintiffs are seeking monetary damages in the amount of $13.2 million . Some of the claims with respect to ALSNA appear to relate to exposure to products of a business acquired by ALSNA. To the extent such exposure occurred prior to the acquisition, ALSNA intends to seek indemnification from the seller. ALSNA filed its answer in May 2014. From time to time, in the ordinary course of our business, we contest tax assessments received by our subsidiaries in various jurisdictions. Our contested tax assessments have been most prevalent in Brazil, where the tax regime is complex, and the administrative and judicial procedures for resolving disputed tax assessments are expensive and time-consuming. In addition, short of simply paying the entire amount demanded, including penalties, interest, and attorney’s fees, it is not possible to settle disputed tax assessments other than by submission for inclusion in formal tax amnesty programs announced by the Brazilian federal or state governments from time to time at irregular intervals. The terms of such amnesty programs vary, but generally offer the possibility of reduced interest and penalties. In the past, Arysta has submitted selected contested tax matters for inclusion in such amnesty programs in Brazil, when it appeared prudent to management to do so, and we are currently contesting several tax assessments at various stages of the applicable administrative and judicial processes, with a combined amount at issue, including interest and penalties, of approximately BRL 41.3 million ( $13.3 million , based on the BRL/USD exchange rate of 0.3223 on June 30, 2015 ). Because tax matters in Brazil historically take many years to resolve, it is very difficult to estimate when these matters will be finally resolved. Based on management's judgments, the Company does not expect it will incur a material loss in excess of accrued liabilities. In February 2015, MacDermid, as plaintiff, settled a litigation with Cookson Group plc, Enthone Inc., Cookson Electronics and David North, as defendants, for $25.0 million . The litigation related to certain corporate activities that occurred between MacDermid and the defendants in 2006 and 2007. On April 3, 2015, the Company received part of the settlement in the amount of $16.0 million , and placed the remainder, net of legal costs, into escrow for future distribution in accordance with the pending litigation provisions of our Business Combination Agreement and Plan of Merger dated as of October 10, 2013.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES For the three months ended June 30, 2015 and 2014 , income tax benefit totaled $0.2 million and $4.1 million , respectively. The Company's effective tax rate in the second quarter of 2015 was 2.7% on pre-tax losses of $9.3 million , compared to an effective tax rate of 158.2% on pre-tax losses of $2.6 million in the second quarter of 2014 . The difference between the statutory and effective tax rate for the three months ended June 30, 2015 principally relates to a tax charge of $4.8 million related to a change in valuation allowance due to a change in forecasts impacting foreign tax credit utilization and a tax benefit for the release of a tax reserve of $2.4 million . For the six months ended June 30, 2015 and 2014 , income tax (expense) benefit totaled $(24.5) million and $1.9 million , respectively. The Company's effective tax rate for the six months ended June 30, 2015 was (224.7)% on pre-tax losses of $10.9 million , compared to an effective tax rate of 30.5% on pre-tax losses of $6.4 million for the six months ended June 30, 2014 . The difference between the statutory and effective tax rate for the six months ended June 30, 2015 is principally related to a tax expense for the establishment of a $23.8 million valuation allowance on foreign tax credit carryovers as a result of the impact of the Arysta Acquisition and losses that did not produce tax benefits having a greater impact in the current period than in the prior year period. The assessment of the need for a valuation allowance requires management to make estimates and assumptions about future earnings, reversal of existing temporary differences and available tax planning strategies. As a result of the impact of the Arysta Acquisition, the Company believes it is more likely than not that the full value of the foreign tax credit carryovers will not be realizable. Consequently, a valuation allowance of $19.0 million was recorded discretely in the first quarter of 2015. The valuation allowance was increased by $4.8 million in the second quarter of 2015 due to changes in forecasts. The amount of unrecognized tax benefits was $67.8 million and $27.7 million at June 30, 2015 and December 31, 2014 , respectively, of which $36.3 million would reduce our effective tax rate if recognized. The increase was primarily due to the historical Arysta unrecognized tax benefits assumed. Accrued interest and penalties related to unrecognized tax benefits were $9.7 million and $4.7 million at June 30, 2015 and December 31, 2014 , respectively. The Company recognized interest and penalties of $0.1 million and $0.4 million related to unrecognized tax benefits in the income tax provision for the three and six months ended June 30, 2015 , respectively. The remainder of the increase was due to the historical Arysta interest and penalties assumed. The unrecognized tax benefits could be reduced by $3.3 million over the next 12 months as a result of the lapse of statutes of limitations in various jurisdictions. The Company is subject to U.S. Federal income tax as well as income tax in multiple state and foreign jurisdictions. The open tax years for major jurisdictions were as follows: Major Jurisdictions Open Years Belgium 2008 through current Brazil 2009 through current China 2011 through current France 2010 through current Japan 2009 through current Mexico 2009 through current South Africa 2009 through current United Kingdom 2008 through current United States 2011 through current The Company is undergoing an audit in France for tax years 2010 through 2012 and in Mexico for tax year 2013. Finally, the Company has been notified by the tax authorities of their intent to initiate an audit in Belgium for tax years 2008 through 2013.

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	VARIABLE INTEREST ENTITIES In connection with the Arysta Acquisition in February 2015, the Company acquired ownership in two distributors deemed to be variable interest entities. Saphyto S.A. The Company holds a 45.0% interest in its product distributor, Saphyto S.A. The Company has determined that it is the primary beneficiary of the activities of Saphyto S.A., as approximately 94.0% of the distributor's sales are based on the Company's products and it has the power to direct activities impacting Saphyto S.A.'s economic performance. The Company is responsible for granting licenses to Saphyto S.A. to sell products and providing technical assistance and feedback on internal operations and controls. The Company and Saphyto's management jointly define the commercial, financial and technical strategy of Saphyto S.A., including pricing. As a result, the activities of Saphyto S.A. are consolidated in the Company's Condensed Consolidated Financial Statements. The following table summarizes the carrying amounts of Saphyto S.A.’s assets and liabilities included in the Company’s Condensed Consolidated Balance Sheet at June 30, 2015: (amounts in millions) June 30, Assets and Liabilities of Saphyto S.A. Cash and cash equivalents $ — Other current assets 13.1 Property, plant and equipment 1.2 Other non-current assets 0.3 Total assets $ 14.6 Current liabilities 10.5 Total liabilities $ 10.5 The capital structure of Saphyto S.A. includes total owner's equity of $4.1 million and short term borrowings of $1.0 million as of June 30, 2015 . Société des Produits Industriels et Agricoles, or SPIA The Company holds a 31.95% interest in its product distributor, SPIA. Approximately 90% of sales generated in SPIA are attributable to the Company's products. The Company is responsible for the development of SPIA's sales for export, administrative and accounting support, and technical support sales. The Company has determined that although it receives a disproportionate amount of economic benefit as compared to its ownership interest, it is not the primary beneficiary of the activities of SPIA, as the majority shareholder of SPIA holds a 50.9% interest and exercises control through voting rights. As a result, the Company has applied the equity method of accounting to its interest in SPIA and is reflected in "Other assets" in the Company's Condensed Consolidated Balance Sheet. The equity investment balance totaled $1.3 million as of June 30, 2015 , representing the Company's maximum exposure to loss. SPIA's total assets were approximately $4.3 million as of June 30, 2015 . The capital structure of SPIA includes total owner's equity of approximately $4.3 million .

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS RHSA Immediately prior to the closing of the MacDermid Acquisition, each Retaining Holder entered into a RHSA pursuant to which they agreed to exchange their respective interests in MacDermid Holdings for shares of PDH Common Stock, at an exchange rate of $11.00 per share plus, with respect to the common, class A and class B unit equity interests of MacDermid Holdings held by the Retaining Holder, (i) a proportionate share of a contingent interest in certain pending litigation, and (ii) a proportionate share of up to $100 million of contingent purchase price payable upon the attainment of certain EBITDA and stock trading price performance metrics during the seven -year period following the closing of the MacDermid Acquisition. The resulting non-controlling interest percentage for the Retaining Holders was 6.36% at June 30, 2015 and 6.67% at December 31, 2014 . Pursuant to the RHSA, until the earlier of (1) the seventh anniversary of the MacDermid Acquisition (being October 31, 2020) and (2) such date on which all shares of PDH Common Stock held by the Retaining Holders have been converted to shares of our common stock, the Company has agreed to, among certain other covenants, obtain written consent prior to issuing additional securities, or instruments convertible, exchangeable or exercisable for securities. Advisory Services Agreement The Company is party to an Advisory Services Agreement with Mariposa Capital, LLC, an affiliate of one of our founder directors, whereby Mariposa Capital, LLC is entitled to receive an annual fee equal to $2.0 million , payable in quarterly installments. This agreement is automatically renewed for successive one -year terms unless either party notifies the other party in writing of its intention not to renew this agreement no later than 90 days prior to the expiration of the term. For each of the three month periods ended June 30, 2015 and 2014 , the Company incurred advisory fees under the agreement totaling $0.5 million , and for each of the six month periods ended June 30, 2015 and 2014 , the Company incurred advisory fees totaling $1.0 million . Registration Rights Agreements On November 7, 2013, the Company entered into a registration rights agreement with Pershing Square on behalf of funds managed by Pershing Square pursuant to which it agreed to file a resale registration statement for the resale of the shares those funds own from time to time promptly after becoming eligible to utilize a Form S-3. The Company became eligible to file a registration statement on Form S-3 on January 23, 2015, and initially filed a registration statement on February 2, 2015 as required by this registration rights agreement. This registration statement was amended on February 12, 2015 and was declared effective on February 20, 2015.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company continuously evaluates all operations to identify opportunities to improve profitability by leveraging existing infrastructure to reduce operating costs and respond to overall economic conditions. Restructuring expenses were recorded in the segments as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Performance Applications $ 1.4 $ 0.4 $ 2.9 $ 0.4 Agricultural Solutions 10.7 — 10.8 — Total restructuring $ 12.1 $ 0.4 $ 13.7 $ 0.4 The restructuring plans initiated in the Performance Applications segment relate to cost saving opportunities associated with a realignment of this segment's footprint in the United States. The restructuring plans initiated in the Agricultural Solutions segment primarily relate to cost saving opportunities associated with the integration of the Arysta, CAS and Agriphar Acquisitions. There are no material additional costs expected to be incurred related to these discrete restructuring plans. At June 30, 2015 and December 31, 2014 , restructuring liability totaled $0.7 million and $1.6 million , respectively, and are included in "Other current liabilities" in the Condensed Consolidated Balance Sheets. Restructuring expenses were recorded as follows in the Condensed Consolidated Statements of Operations: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Cost of sales $ 1.2 $ — $ 1.2 $ — Selling, technical, general and administrative 10.9 0.4 12.5 0.4 Total restructuring $ 12.1 $ 0.4 $ 13.7 $ 0.4

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION During the first quarter of 2015, the Company completed certain changes to its organizational structure that resulted in a change to the Company's reportable business segments. As a result, the Performance Materials and Graphic Solutions reportable segments were combined into the Performance Applications reportable segment, and the AgroSolutions reportable segment was re-branded to Agricultural Solutions. The new segment reporting structure represents businesses for which separate financial information is utilized by the chief operating decision maker, or CODM, for purpose of allocating resources and evaluating performance. Each reportable segment has its own president, who reports to the CODM. The Performance Applications segment formulates and markets dynamic chemistry solutions that are used in electronics, automotive production, oil and gas production, drilling, commercial packaging and printing. Our products include surface and coating materials, water-based hydraulic control fluids and photopolymers. We sell these products worldwide. In conjunction with the sale of our products, we provide extensive technical service and support to ensure superior performance of their application. Within this segment, the Company provides specialty chemicals to the following industries; Electronics, Industrial, Offshore and Commercial Packing and Printing. For the electronics industry, we design and formulate a complete line of proprietary “wet” dynamic chemistries that our customers use to process the surface of the printed circuit boards and other electronic components they manufacture. For the industrials, our dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process. For the offshore industry, we produce water-based hydraulic control fluids for major oil companies and drilling contractors for offshore deep water production and drilling applications. For the commercial packaging and printing industries, we produce photopolymers through an extensive line of flexographic plates, used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, we also produce photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. The Agricultural Solutions segment is based on a solutions-oriented business model that focuses on product innovation to address an ever-increasing need for higher crop yield and quality. We offer a wide variety of proven plant health and pest control products to growers, which are comprised of specific target applications in the following major product lines: adjuvants; fungicides; herbicides; home applications (home and garden and ectoparasiticides); insecticides; miticides; plant growth regulators; and seed treatments. We refer to herbicides, insecticides, fungicides and seed treatment categories, based on patented or proprietary off-patent AIs, as our Global Value Added Portfolio, or GVAP. Our product portfolio also includes biosolutions (biostimulants, innovative nutrition and biocontrol), and regional off-patent AIs that complement our principal product lines. In addition, we offer certain non-crop products, including animal health products, such as honey bee protective miticides and certain veterinary vaccines. The Company evaluates the performance of its operating segments based on net sales and adjusted EBITDA. Adjusted EBITDA for each segment is calculated by taking net income and adding back interest expense, income tax expense (benefit), depreciation expense and amortization expense. This amount is further adjusted for acquisition-related expenses. Adjusted EBITDA for each segment also includes an allocation of corporate costs such as corporate salary, wages, equity compensation expense and legal costs. The following table summarizes financial information regarding each reportable segment’s results of operations for the periods presented. The historical periods have been recasted to reflect the change to the Company's reportable business segment structure during the first quarter of 2015. Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Net Sales (from external customers): Performance Applications $ 181.5 $ 189.1 $ 361.8 $ 372.8 Agricultural Solutions 493.6 — 848.1 — Consolidated net sales 675.1 189.1 1,209.9 372.8 Adjusted EBITDA: Performance Applications 53.9 48.2 102.4 94.1 Agricultural Solutions 113.7 — 195.7 — Adjusted EBITDA $ 167.6 $ 48.2 $ 298.1 $ 94.1 The following table reconciles Adjusted EBITDA to Net loss attributable to stockholders: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Adjusted EBITDA $ 167.6 $ 48.2 $ 298.1 $ 94.1 Adjustments to reconcile to net loss attributable to stockholders: Interest expense (52.5 ) (7.9 ) (93.0 ) (15.7 ) Depreciation and amortization expense (66.1 ) (21.4 ) (114.3 ) (38.3 ) Restructuring and related expenses (12.1 ) (0.4 ) (13.7 ) (0.4 ) Manufacturer's profit in inventory adjustment (20.7 ) — (56.7 ) (12.0 ) Acquisition transaction costs (24.1 ) (10.5 ) (55.4 ) (10.5 ) Non-cash fair value adjustment to contingent consideration (0.9 ) (10.8 ) (3.6 ) (23.8 ) Legal settlement 16.0 — 16.0 — Acquisition put option expiration — — 3.0 — Foreign exchange gains on foreign denominated external and internal debt (17.9 ) — 6.1 — Other income 1.4 0.2 2.6 0.2 Loss before income taxes and non-controlling interest (9.3 ) (2.6 ) (10.9 ) (6.4 ) Income tax benefit (expense) 0.2 4.1 (24.5 ) 1.9 Net income attributable to the non-controlling interests (3.1 ) (1.9 ) (3.5 ) (3.3 ) Net loss attributable to stockholders $ (12.2 ) $ (0.4 ) $ (38.9 ) $ (7.8 )

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS Proposed Alent Acquisition On July 13, 2015, Platform and Alent issued an announcement, pursuant to Rule 2.7 of the U.K. Takeover Code, disclosing the terms of a recommended offer by MacDermid Performance Acquisitions Ltd., a private limited company registered in England and Wales, and an indirect subsidiary of Platform, to acquire all of the shares of Alent pursuant to a scheme of arrangement to be implemented under the U.K. Companies Act. In connection with the Alent Acquisition, on July 13, 2015, (i) Platform, MacDermid Performance Acquisitions Ltd., and Alent entered into a co-operation agreement and (ii) Platform, certain subsidiary guarantors, Credit Suisse AG and certain other Credit Suisse AG affiliates entered into a $1.88 billion interim facility letter. Pursuant to the terms of the Alent Acquisition, each shareholder of Alent is entitled to receive 503 pence in cash for each ordinary share of Alent. The scheme of arrangement will also include a partial share alternative under which eligible shareholders of Alent can elect to receive Platform common stock in lieu of part or all of the cash consideration that they would otherwise be entitled to receive in exchange for their Alent Shares on the basis of 0.31523 new Platform's shares for every Alent share. Such alternative is to be limited to the issue of new Platform shares in respect of approximately 21.9% of Alent’s issued share capital at close of business on July 10, 2015. The Alent Acquisition values Alent’s entire share capital at approximately £1.35 billion ( $2.10 billion , based on the GBP/USD exchange rate of 1.5517 on July 10, 2015). On July 13, 2015, in connection with the Alent Acquisition, Platform and certain subsidiary guarantors entered into an interim facility letter with Credit Suisse AG and certain of its affiliates pursuant to which they committed, subject to the terms therein, to provide Platform with a $1.88 billion interim senior unsecured term loan facility. Platform expects to replace this term loan facility with more permanent financing before or after the closing of the Alent Acquisition. The commitments under the interim facility letter, unless previously terminated, will terminate on the earlier of (i) the date on which the consummation of the Alent Acquisition is announced without the making of any advances under the term loan facility and (ii) July 13, 2016. The facility amount of $1.88 billion will be reduced by the net proceeds of any securities or other borrowings raised or issued in connection with the Alent Acquisition. The interim facility letter is subject to other terms and conditions customary for commitments and facilities of this type including certain affirmative covenants, negative covenants, conditions precedent and events of default. On the date of the Rule 2.7 announcement, and as provided for therein, Platform and MacDermid Performance Acquisitions Ltd. received an irrevocable undertaking from Cevian Capital II Master Fund LP, the largest shareholder of Alent, to vote in favor of the scheme of arrangement and elect for the partial share alternative in respect of its entire beneficial ownership of 58,432,694 of Alent's shares. If no shareholders of Alent apart from Cevian Capital II Master Fund LP elect to receive new Platform shares, Cevian Capital II Master Fund LP will be issued the full amount of new Platform shares available under the partial share alternative. The Acquisition is conditioned upon, among other things, (i) approval of the scheme of arrangement and the related resolutions by the requisite majorities of Alent shareholders and the sanction of the scheme by the High Court of England and Wales, (ii) the expiration or termination of the applicable waiting period under the HSRA Act, as well as the receipt of certain other clearances under the antitrust laws of other jurisdictions in which an antitrust filing is required to be made and associated approvals and clearances and (iii) the absence of an adverse change or deterioration in the business, assets, financial or trading position or profits or prospects of any member of the Alent group, which is material in the context of the group taken as a whole. If the Alent Acquisition is not consummated, we may be required to pay to Alent certain costs and expenses relating to the Alent Acquisition, including a break-up fee of £27 million in the event we invoke a regulatory approvals condition on or prior to July 13, 2016 or where certain regulatory approvals conditions are not satisfied or waived on July 13, 2016, as further provided in the co-operation agreement with Alent. Both companies' boards of directors have unanimously recommended the transaction, which is expected to close in late 2015 or early 2016, subject to customary closing conditions for transactions of this nature. MacDermid Performance Acquisitions Ltd. reserves the right, subject to the prior consent of the U.K. Panel on Takeovers and Mergers and the terms of the co-operation agreement, to elect to implement the Alent Acquisition by way of a takeover offer (as such term is defined in the U.K. Companies Act). Following closing of the transaction, Platform will remain a NYSE listed company domiciled in the United States. There can be no assurances that the Alent Acquisition will be consummated. Please see the risk factors included in this Quarterly Report for risks regarding the proposed Alent Acquisition. In connection with the Alent Acquisition, during July 2015, the Company entered into no-cost, deal contingent forward purchases of £1.06 billion ( $1.64 billion , based on the GBP/USD exchange rate of 1.5487 on July 13, 2015). The price for 50% of the forward purchases is set; however, it is dependent upon the timing of the closing of the proposed Alent Acquisition. The price for the remaining 50% allows for the Company to benefit from a weakening of the GBP relative to the USD while being protected against price movements above a maximum average of GBP/USD exchange rate of 1.6244 . Interest rate swaps On August 5, 2015, the Company entered into a series of pay fixed, receiving floating interest rate swaps with respect to a portion of its indebtedness. The swaps effectively fix the floating rate portion of the interest payments on approximately $1.20 billion of our USD denominated debt and €286 million of our Euro denominated debt at 1.96% and 1.20% , respectively, from September 2015 through June 2020.

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting, Policy	Basis of Presentation These unaudited interim Condensed Consolidated Financial Statements and related information have been prepared in accordance with U.S. GAAP for interim financial information and in accordance with the applicable rules and regulations of the SEC. Accordingly, they do not include all of the disclosures required in connection with annual financial statements. These unaudited interim Condensed Consolidated Financial Statements reflect all adjustments that are, in the opinion of management, normal, recurring and necessary for a fair statement of the results of operations. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included in the Company’s Annual Report.
New Accounting Pronouncements, Policy	Accounting Policies Recently Adopted and Pending Pronouncements Revenue from Contracts with Customers (Topic 606) - In August 2015, the FASB issued ASU No. 2015-14 “Deferral of the Effective Date,” which defers the effective date of ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)," for all entities by one year. As a result, the provisions of ASU No. 2014-09 will be effective prospectively for fiscal years and interim periods beginning after December 15, 2017. ASU No. 2014-09 (1) removes inconsistencies and weaknesses in revenue requirements, (2) provides a more robust framework for addressing revenue issues, (3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, (4) provides more useful information to users of financial statements through improved disclosure requirements and (5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company continues to evaluate the impact of this ASU. Inventory (Topic 330) - In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory.” Under the updated guidance, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is in the process of evaluating the impact of this new ASU, but does not expect it to have a material impact on its financial statements. Fair Value Measurement (Topic 820) - In May 2015, the FASB issued ASU No. 2015-07, “ Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent).” This update eliminates diversity in practice related to investments whose fair value is measured using net asset values as a practical expedient, and removes the requirement to categorize such investments within the fair value hierarchy. The guidance is effective retrospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company continues to evaluate the impact of this new ASU, but does not expect it to have a material impact on its financial statements. Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40 ) - In April 2015, the FASB issued ASU No. 2015-05, “ Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.” This update provides explicit guidance to customers utilizing a cloud computing solution to help determine whether such an arrangement include a software license, in which case the accounting applied would be similar to that of other software license arrangements. Otherwise, the arrangement would be accounted for as a service contract. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Interest - Imputation of Interest (Subtopic 835-30) - In April 2015, the FASB issued ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs.” This update eliminates the difference in the presentation of debt issuance costs and debt discount and premiums by requiring that debt issuance costs be presented as deductions from the carrying value of the related debt, in a manner similar to debt discounts. The guidance is effective retroactively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company adopted this ASU as of June 30, 2015, and reclassified approximately $48.6 million and $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of June 30, 2015 and December 31, 2014, respectively. Derivatives and Hedging (Topic 815) - In November 2014, the FASB issued ASU No. 2014-16, “ Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force).” Under current practice, there were predominantly two methods used to evaluate whether the nature of the host contract in a hybrid financial instrument is more akin to debt or equity: one considered all the features including the embedded and the other excluded the embedded derivative in the consideration. This update eliminates the difference in practice by clarifying that the evaluation should be based on all the instrument’s features, including the embedded derivative, and that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. The guidance is effective for fiscal years and interim periods beginning after December 15, 2015 and is applied in a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of our fiscal year 2016. Early adoption, including in an interim period, is permitted. The Company adopted the provision of this ASU during the first quarter of 2015, with the issuance of the Series B Convertible Preferred Stock. This ASU did not have a material impact on the Company's financial statements, as there were no hybrid financial instruments requiring retrospective application

Acquisitions of Businesses (Tab

Acquisitions of Businesses (Tables)	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	Revenues contributed by the Arysta, CAS and Agriphar Acquisitions for the three and six months ended June 30, 2015 were as follows: (amounts in millions) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Arysta $ 341.9 $ 519.4 CAS 105.2 208.6 Agriphar 46.4 120.0 Total $ 493.5 $ 848.0 As the integration of the Arysta, CAS and Agriphar Acquisitions continues, discrete revenues reported by the businesses are being effected by the integration process. and are becoming less comparable to prior periods. Arysta, CAS and Agriphar Acquisitions had net (loss) income for the three and six months ended June 30, 2015 as follows: (amounts in millions) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Arysta $ (61.5 ) $ (65.8 ) CAS 0.9 (27.5 ) Agriphar 4.2 22.4 Total $ (56.4 ) $ (70.9 )
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the consideration transferred and transaction related costs incurred to acquire Arysta, CAS and Agriphar and the applicable amounts of identified assets acquired and liabilities assumed at the acquisition date: (amounts in millions) Arysta CAS Agriphar Consideration Cash, net $ 2,856.2 $ 983.1 $ 350.2 Equity Instruments 645.9 52.0 16.6 Derivative liability — — 3.5 Total Consideration 3,502.1 1,035.1 370.3 Transaction related costs 34.2 43.7 5.0 Identifiable Assets acquired and Liabilities Assumed Accounts receivable 675.5 154.2 60.1 Inventories 294.8 132.1 42.7 Other current assets 132.2 19.1 0.4 Property, plant and equipment 110.0 24.8 31.7 Identifiable intangible assets 1,639.0 534.0 183.0 Other assets 38.2 21.5 4.5 Current Liabilities (570.4 ) (69.7 ) (47.5 ) Non-current deferred tax liability (489.5 ) (26.7 ) (64.9 ) Other long term liabilities (74.2 ) (13.4 ) (9.0 ) Non-controlling interest (24.6 ) — — Total identifiable net assets 1,731.0 775.9 201.0 Goodwill 1,771.1 259.2 169.3 Total purchase price $ 3,502.1 $ 1,035.1 $ 370.3
Business Acquisition, Pro Forma Information	The following unaudited pro forma summary presents consolidated information of the Company for the three and six months ended June 30, 2015 and 2014 , as if the Arysta Acquisition had occurred on January 1, 2014: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Revenue $ 675.1 $ 591.5 $ 1,297.4 $ 1,080.6 Net income (loss) attributable to stockholders $ 4.4 $ (34.4 ) $ (41.5 ) $ (112.0 )

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The major components of inventory were as follows: (amounts in millions) June 30, December 31, 2014 Finished goods $ 326.8 $ 156.3 Work in process 16.0 — Raw materials and supplies 127.2 49.5 Total inventory, net $ 470.0 $ 205.8

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	The major components of property, plant and equipment, including equipment under capital leases, were as follows: (amounts in millions) June 30, December 31, 2014 Land and leasehold improvements $ 42.1 $ 36.6 Buildings and improvements 77.8 44.4 Machinery, equipment, fixtures and software 166.5 99.0 Assets under capital leases 21.7 8.9 308.1 188.9 Less: accumulated depreciation (41.9 ) (18.1 ) 266.2 170.8 Construction in process 14.4 4.2 Property, plant and equipment, net $ 280.6 $ 175.0

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by segment were as follows: (amounts in millions) Performance Applications Agricultural Solutions Total December 31, 2014 $ 961.2 $ 444.1 $ 1,405.3 Addition from acquisitions — 1,697.1 1,697.1 Purchase accounting adjustments — 43.8 43.8 Foreign currency translation (23.9 ) (109.5 ) (133.4 ) June 30, 2015 $ 937.3 $ 2,075.5 $ 3,012.8
Schedule of Finite-Lived Intangible Assets	June 30, 2015 December 31, 2014 (amounts in millions) Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Customer lists $ 946.8 $ (104.5 ) $ 842.3 $ 613.6 $ (71.6 ) $ 542.0 Developed technology 1,855.5 (177.0 ) 1,678.5 760.5 (50.8 ) 709.7 Tradenames 19.0 (2.2 ) 16.8 19.7 (1.0 ) 18.7 Non-compete agreements 1.9 (0.3 ) 1.6 1.9 (0.1 ) 1.8 Total $ 2,823.2 $ (284.0 ) $ 2,539.2 $ 1,395.7 $ (123.5 ) $ 1,272.2

Equity Compensation Plans (Tabl

Equity Compensation Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	Six Months Ended June 30, 2015 Total RSUs Stock Options Equity Classified Liability Classified December 31, 2014 721,933 142,110 329,823 250,000 Granted 464,024 250,622 213,402 — Exercised (75,000 ) — — (75,000 ) Forfeited (25,984 ) (25,984 ) — — June 30, 2015 1,084,973 366,748 543,225 175,000

Pension, Post-Retirement and 35

Pension, Post-Retirement and Post-Employment Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Costs	The components of net periodic pension and post-retirement benefit costs for the three and six months ended June 30, 2015 and 2014 were as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Pension & SERP Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic (benefit) cost: Service cost $ — $ 0.2 $ — $ 0.2 $ — $ 0.4 $ — $ 0.4 Interest cost on the projected benefit obligation 1.6 0.5 1.7 0.8 3.2 1.0 3.4 1.6 Expected return on plan assets (2.4 ) (0.5 ) (2.4 ) (0.9 ) (4.8 ) (1.0 ) (4.8 ) (1.8 ) Net periodic (benefit) cost $ (0.8 ) $ 0.2 $ (0.7 ) $ 0.1 $ (1.6 ) $ 0.4 $ (1.4 ) $ 0.2 Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Post-retirement Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic cost: Interest cost on the projected benefit obligation $ 0.1 $ — $ 0.1 $ — $ 0.2 $ — $ 0.2 $ — Net periodic cost $ 0.1 $ — $ 0.1 $ — $ 0.2 $ — $ 0.2 $ —

Debt, Capital Leases, Financi36

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s debt and capital lease obligations consisted of the following: (amounts in millions) June 30, December 31, 2014 Borrowings under lines of credit, $ 22.4 $ — USD Notes, due 2022, 1,079.5 — EUR Notes, due 2023, 383.4 — First lien secured credit facility and term loan, due 2020, 739.3 743.0 USD Incremental Loan, due 2020, 291.7 292.7 New Tranche B Term Loan, due 2020, 121.9 121.7 New Tranche B-2 Term Loan, due 2020, 482.1 — Euro Tranche Term Loan, due 2020, 225.7 246.2 New Euro Tranche Term Loan, due 2020, 90.3 — Capital lease obligations 4.5 2.0 Total debt and capital lease obligations 3,418.4 1,405.6 Less: current portion debt and capital lease obligations (16.8 ) (13.2 ) Total long-term debt and capital lease obligations $ 3,401.6 $ 1,392.4
Schedule of Maturities of Long-term Debt	Minimum principal payments on long-term debt and capital leases were as follows: (amounts in millions) Principal Payments Year ending December 31, 2015 - remaining $ 10.9 2016 20.8 2017 20.5 2018 20.4 2019 20.4 2020 1,892.6 Thereafter 1,492.1 Total $ 3,477.7

Derivative Instruments (Tables)

Derivative Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets: (amounts in millions) June 30, December 31, 2014 U.S. Dollar Amount U.S. Dollar Amount Derivatives not designated as hedging instruments: Assets Balance Sheet Location Foreign exchange contracts Prepaid expenses & other current assets $ 0.7 $ — Liabilities Balance Sheet Location Foreign exchange contracts Other current liabilities — 0.1 Total derivative contracts $ 0.7 $ (0.1 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The following tables present the Company’s financial instruments, assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurement Using (amounts in millions) June 30, Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 29.2 $ 29.2 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Derivatives 0.7 — 0.7 — Total $ 32.2 $ 30.7 $ 1.5 $ — Liability Category Long term contingent consideration $ 67.5 $ — $ — $ 67.5 Total $ 67.5 $ — $ — $ 67.5 Fair Value Measurement Using (amounts in millions) December 31, 2014 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 15.4 $ 15.4 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Total $ 17.7 $ 16.9 $ 0.8 $ — Liability Category Long term contingent consideration $ 63.9 $ — $ — $ 63.9 Derivatives 0.1 — 0.1 — Total $ 64.0 $ — $ 0.1 $ 63.9
Fair Value Measurements, Nonrecurring	The following table presents the carrying value and estimated fair value of the Company’s long term debt and capital lease obligations: (amounts in millions) June 30, 2015 December 31, 2014 Long term debt - including current portion Carrying Value Fair Value Carrying Value Fair Value USD Notes, due 2022, interest at 6.50% $ 1,079.5 $ 1,117.3 $ — $ — EUR Notes, due 2023, interest at 6.00% 383.4 384.3 — — First Lien Credit Facility 739.3 738.3 743.0 720.7 USD Incremental Loan 291.7 291.4 292.7 283.9 New Tranche B Term Loan 121.9 121.8 121.7 118.0 New Tranche B-2 Term Loan 482.1 481.5 — — Euro Tranche Term Loan 225.7 225.4 246.2 238.8 New Euro Tranche Term Loan 90.3 90.2 — — Capital lease obligations 4.5 4.5 2.0 2.6 Total $ 3,418.4 $ 3,454.7 $ 1,405.6 $ 1,364.0

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	A summary of the changes in each component of accumulated other comprehensive (loss) income, net of tax for the three months and six months ended June 30, 2015 and 2014 were as follows: Three Months Ended June 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Loss Balance at March 31, 2015 $ (547.5 ) $ (15.4 ) $ — $ — $ 15.1 $ (547.8 ) Other comprehensive income (loss) before reclassifications, net 161.5 — 0.3 — (1.6 ) 160.2 Reclassifications, pretax — — — — — — Tax benefit reclassified — — — — — — Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Six Months Ended June 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2014 $ (122.2 ) $ (14.9 ) $ 0.1 $ — $ 6.4 $ (130.6 ) Other comprehensive (loss) income before reclassifications, net (263.8 ) — 0.2 — 7.1 (256.5 ) Reclassifications, pretax — — — — — — Tax benefit reclassified — (0.5 ) — — — (0.5 ) Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Three Months Ended June 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2014 $ 2.7 $ 2.0 $ — $ — $ — $ 4.7 Other comprehensive income before reclassifications, net 19.7 — 0.1 — (1.3 ) 18.5 Reclassifications, pretax — — (0.1 ) (0.1 ) — (0.2 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1 Six Months Ended June 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2013 $ (0.6 ) $ 1.8 $ — $ 0.1 $ — $ 1.3 Other comprehensive income before reclassifications, net 23.0 0.2 0.1 — (1.3 ) 22.0 Reclassifications, pretax — — (0.1 ) (0.2 ) — (0.3 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A computation of the weighted average shares outstanding for the three and six months ended June 30, 2015 and 2014 follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions, except per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders $ (12.2 ) $ (0.4 ) $ (38.9 ) $ (7.8 ) Basic weighted average common stock outstanding 192.8 128.6 192.3 117.9 Convertible and performance-based stock (1) — — — — Dilutive weighted average common stock outstanding 192.8 128.6 192.3 117.9 Earnings per share attributable to common stockholders: Basic $ (0.06 ) $ — $ (0.20 ) $ (0.07 ) Diluted $ (0.06 ) $ — $ (0.20 ) $ (0.07 ) 1 No share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	For the three and six months ended June 30, 2015 and 2014 , the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because performance targets were not yet achieved for awards contingent upon performance. Three Months Ended June 30, Six Months Ended June 30, (amounts in thousands) 2015 2014 2015 2014 Number of shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock 2,789 11,279 2,789 11,279 Number of shares issuable upon conversion of warrants — — — 2,243 Number of shares issuable upon conversion of PDH Common Stock 8,213 8,775 8,213 8,775 Number of shares issuable upon conversion of Series A Preferred Stock 2,000 2,000 2,000 2,000 Number of shares issuable upon conversion of Series B Convertible Preferred Stock 22,108 — 16,733 — Number of shares contingently issuable for the contingent consideration 1,347 713 1,333 713 Number of shares issuable upon conversion of the 401k exchange rights — — — 544 Number of stock options 69 88 79 80 Number of restricted stock shares and units 161 2 89 1 36,687 22,857 31,236 25,635

Operating Lease Commitments (Ta

Operating Lease Commitments (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Rent Expense	Total rental expense for operating leases was as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Rent Expense $ 6.1 $ 2.5 $ 10.4 $ 5.0
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum non-cancelable operating lease commitments were as follows: (amounts in millions) Operating Lease Payment Year ending December 31, 2015, remaining $ 7.0 2016 9.5 2017 6.5 2018 4.8 2019 3.8 2020 3.1 Thereafter 12.8 $ 47.5

Contingencies, Environmental 42

Contingencies, Environmental and Legal Matters (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Change in Asset Retirement Obligation	Changes in the Company’s AROs were as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 AROs, beginning of period $ 17.4 $ 4.9 $ 18.5 $ 4.8 Acquisitions 0.4 0.3 0.4 0.3 Accretion expense 0.2 0.2 0.5 0.3 Remeasurements (0.7 ) — (0.7 ) — Foreign currency adjustments 0.4 — (1.0 ) — AROs, end of period $ 17.7 $ 5.4 $ 17.7 $ 5.4

Income Taxes Income Taxes (Tabl

Income Taxes Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Summary of Open Tax Years	The Company is subject to U.S. Federal income tax as well as income tax in multiple state and foreign jurisdictions. The open tax years for major jurisdictions were as follows: Major Jurisdictions Open Years Belgium 2008 through current Brazil 2009 through current China 2011 through current France 2010 through current Japan 2009 through current Mexico 2009 through current South Africa 2009 through current United Kingdom 2008 through current United States 2011 through current

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The following table summarizes the carrying amounts of Saphyto S.A.’s assets and liabilities included in the Company’s Condensed Consolidated Balance Sheet at June 30, 2015: (amounts in millions) June 30, Assets and Liabilities of Saphyto S.A. Cash and cash equivalents $ — Other current assets 13.1 Property, plant and equipment 1.2 Other non-current assets 0.3 Total assets $ 14.6 Current liabilities 10.5 Total liabilities $ 10.5

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Restructuring expenses were recorded as follows in the Condensed Consolidated Statements of Operations: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Cost of sales $ 1.2 $ — $ 1.2 $ — Selling, technical, general and administrative 10.9 0.4 12.5 0.4 Total restructuring $ 12.1 $ 0.4 $ 13.7 $ 0.4 Restructuring expenses were recorded in the segments as follows: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Performance Applications $ 1.4 $ 0.4 $ 2.9 $ 0.4 Agricultural Solutions 10.7 — 10.8 — Total restructuring $ 12.1 $ 0.4 $ 13.7 $ 0.4

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table summarizes financial information regarding each reportable segment’s results of operations for the periods presented. The historical periods have been recasted to reflect the change to the Company's reportable business segment structure during the first quarter of 2015. Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Net Sales (from external customers): Performance Applications $ 181.5 $ 189.1 $ 361.8 $ 372.8 Agricultural Solutions 493.6 — 848.1 — Consolidated net sales 675.1 189.1 1,209.9 372.8 Adjusted EBITDA: Performance Applications 53.9 48.2 102.4 94.1 Agricultural Solutions 113.7 — 195.7 — Adjusted EBITDA $ 167.6 $ 48.2 $ 298.1 $ 94.1 The following table reconciles Adjusted EBITDA to Net loss attributable to stockholders: Three Months Ended June 30, Six Months Ended June 30, (amounts in millions) 2015 2014 2015 2014 Adjusted EBITDA $ 167.6 $ 48.2 $ 298.1 $ 94.1 Adjustments to reconcile to net loss attributable to stockholders: Interest expense (52.5 ) (7.9 ) (93.0 ) (15.7 ) Depreciation and amortization expense (66.1 ) (21.4 ) (114.3 ) (38.3 ) Restructuring and related expenses (12.1 ) (0.4 ) (13.7 ) (0.4 ) Manufacturer's profit in inventory adjustment (20.7 ) — (56.7 ) (12.0 ) Acquisition transaction costs (24.1 ) (10.5 ) (55.4 ) (10.5 ) Non-cash fair value adjustment to contingent consideration (0.9 ) (10.8 ) (3.6 ) (23.8 ) Legal settlement 16.0 — 16.0 — Acquisition put option expiration — — 3.0 — Foreign exchange gains on foreign denominated external and internal debt (17.9 ) — 6.1 — Other income 1.4 0.2 2.6 0.2 Loss before income taxes and non-controlling interest (9.3 ) (2.6 ) (10.9 ) (6.4 ) Income tax benefit (expense) 0.2 4.1 (24.5 ) 1.9 Net income attributable to the non-controlling interests (3.1 ) (1.9 ) (3.5 ) (3.3 ) Net loss attributable to stockholders $ (12.2 ) $ (0.4 ) $ (38.9 ) $ (7.8 )

Basis of Presentation and Sig47

Basis of Presentation and Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 04, 2014	Oct. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Feb. 13, 2015	Dec. 31, 2014	Jan. 23, 2014
Business Acquisition [Line Items]
Goodwill			$ 3,012.8		$ 3,012.8			$ 1,405.3
Addition from acquisitions					2,200
Share price (in usd per share)									$ 0.01
Debt issuance costs reclassification from assets to contra-liabilities			48.6		48.6			$ 10.3
Foreign currency translation adjustments			161.5	$ 19.7	(263.7)	$ 23
Mac Dermid [Member]
Business Acquisition [Line Items]
Percentage of ownership	3.00%	97.00%
Arysta [Member]
Business Acquisition [Line Items]
Goodwill							$ 1,771.1
Prior Period Error Related To Purchase Accounting Related To Acquisitions [Member] | Restatement Adjustment [Member] | Arysta [Member]
Business Acquisition [Line Items]
Goodwill			73		$ 73
Foreign currency translation adjustments			$ 73

Acquisitions of Businesses (Det

Acquisitions of Businesses (Details)	Feb. 13, 2015USD ($)	Nov. 03, 2014USD ($)agreementshares	Oct. 01, 2014USD ($)	Oct. 01, 2014EUR (€)	Mar. 31, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)product_line	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Business Acquisition [Line Items]
Transaction related costs						$ 24,100,000	$ 10,500,000	$ 55,400,000	$ 10,500,000
Capital lease obligations						4,500,000		4,500,000		$ 2,000,000
Asset retirement obligations						17,700,000	5,400,000	17,700,000	5,400,000	18,500,000	$ 17,400,000	$ 4,900,000	$ 4,800,000
Option reversal value						2,200,000	$ 500,000	(33,400,000)	$ 600,000
Goodwill acquired								2,200,000,000
Goodwill, expected to be tax deductible						185,000,000		185,000,000
Arysta [Member]
Business Acquisition [Line Items]
Total Consideration	$ 3,502,100,000
Cash, net	2,856,200,000
Common stock restricted shares (in shares)	600,000,000
Equity Instruments	645,900,000
Transaction related costs	$ 34,200,000					4,900,000		27,800,000
CAS [Member]
Business Acquisition [Line Items]
Total Consideration		$ 1,035,100,000
Cash, net		983,100,000
Equity Instruments		52,000,000
Transaction related costs		$ 43,700,000
Business acquisition, shares of common stock issued (in shares) | shares		2,000,000
Number of supply agreements | agreement		6
Capital lease obligations						13,200,000		13,200,000
Depreciation						2,200,000
Asset retirement obligations						13,200,000		$ 13,200,000
Minimum supply agreement term		4 years
Major product lines | product_line								7
Agriphar [Member]
Business Acquisition [Line Items]
Total Consideration			$ 370,300,000	€ 300,000,000
Cash, net			350,200,000
Common stock restricted shares (in shares) | €				€ 711,551
Equity Instruments			16,600,000
Transaction related costs			$ 5,000,000
Option reversal value								$ (3,000,000)
Agriphar Acquisition [Member]
Business Acquisition [Line Items]
First portion of restricted stock transfer								33.33%
Second portion of restricted stock transfer								33.33%
Third portion of restricted stock transfer								33.33%
OMG [Member]
Business Acquisition [Line Items]
Reverse termination fee						62,700,000		$ 62,700,000
Reimbursement of fees and expenses						7,500,000		7,500,000
Certis Europe BV [Member] | CAS [Member]
Business Acquisition [Line Items]
Percentage equity in acquisition		15.00%
Value of the equity interest		$ 15,000,000
Selling, General and Administrative Expenses [Member] | Arysta [Member]
Business Acquisition [Line Items]
Transaction related costs						4,900,000		27,800,000		6,400,000
Selling, General and Administrative Expenses [Member] | CAS [Member]
Business Acquisition [Line Items]
Transaction related costs						4,900,000		9,800,000		33,900,000
Selling, General and Administrative Expenses [Member] | Agriphar Acquisition [Member]
Business Acquisition [Line Items]
Transaction related costs						300,000		800,000		$ 4,200,000
Customer Lists [Member] | Arysta [Member]
Business Acquisition [Line Items]
Intangible asset useful life	20 years
Developed Technology Rights [Member] | Arysta [Member]
Business Acquisition [Line Items]
Intangible asset useful life	12 years
Cash [Member] | CAS [Member]
Business Acquisition [Line Items]
Total Consideration		$ 983,000,000
OMG [Member]
Business Acquisition [Line Items]
Reimbursement of fees and expenses						7,500,000		7,500,000
Apollo [Member]
Business Acquisition [Line Items]
Reimbursement of fees and expenses						$ 7,500,000		$ 7,500,000
Scenario, Forecast [Member] | OMG [Member]
Business Acquisition [Line Items]
Total Consideration					$ 367,000,000

Acquisition of Business (Detail

Acquisition of Business (Details 2) - Jun. 30, 2015 - USD ($) $ in Millions	Total	Total
Business Acquisition [Line Items]
Revenues	$ 493.5	$ 848
Net loss attributable to stockholders	(56.4)	(70.9)
Arysta [Member]
Business Acquisition [Line Items]
Revenues	341.9	519.4
Net loss attributable to stockholders	(61.5)	(65.8)
CAS [Member]
Business Acquisition [Line Items]
Revenues	105.2	208.6
Net loss attributable to stockholders	0.9	(27.5)
Agriphar [Member]
Business Acquisition [Line Items]
Revenues	46.4	120
Net loss attributable to stockholders	$ 4.2	$ 22.4

Acquisitions of Businesses (D50

Acquisitions of Businesses (Details 3) € in Millions, $ in Millions	Feb. 13, 2015USD ($)	Nov. 03, 2014USD ($)	Oct. 01, 2014USD ($)	Oct. 01, 2014EUR (€)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Transaction related costs					$ 24.1	$ 10.5	$ 55.4	$ 10.5
Goodwill					3,012.8		3,012.8		$ 1,405.3
Agriphar [Member]
Business Acquisition [Line Items]
Cash, net			$ 350.2
Equity Instruments			16.6
Derivative liability			3.5
Total Consideration			370.3	€ 300
Transaction related costs			5
Accounts receivable			60.1
Inventories			42.7
Other current assets			0.4
Property, plant and equipment			31.7
Identifiable intangible assets			183
Other assets			4.5
Current Liabilities			(47.5)
Non-current deferred tax liability			(64.9)
Other long term liabilities			(9)
Non-controlling interest			0
Total identifiable net assets			201
Goodwill			169.3
Total purchase price			$ 370.3
Arysta [Member]
Business Acquisition [Line Items]
Cash, net	$ 2,856.2
Equity Instruments	645.9
Derivative liability	0
Total Consideration	3,502.1
Transaction related costs	34.2				$ 4.9		$ 27.8
Accounts receivable	675.5
Inventories	294.8
Other current assets	132.2
Property, plant and equipment	110
Identifiable intangible assets	1,639
Other assets	38.2
Current Liabilities	(570.4)
Non-current deferred tax liability	(489.5)
Other long term liabilities	(74.2)
Non-controlling interest	(24.6)
Total identifiable net assets	1,731
Goodwill	1,771.1
Total purchase price	$ 3,502.1
CAS [Member]
Business Acquisition [Line Items]
Cash, net		$ 983.1
Equity Instruments		52
Derivative liability		0
Total Consideration		1,035.1
Transaction related costs		43.7
Accounts receivable		154.2
Inventories		132.1
Other current assets		19.1
Property, plant and equipment		24.8
Identifiable intangible assets		534
Other assets		21.5
Current Liabilities		(69.7)
Non-current deferred tax liability		(26.7)
Other long term liabilities		(13.4)
Non-controlling interest		0
Total identifiable net assets		775.9
Goodwill		259.2
Total purchase price		$ 1,035.1

Acquisition of Businesses (Deta

Acquisition of Businesses (Details 4) - Arysta [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Revenue	$ 675.1	$ 591.5	$ 1,297.4	$ 1,080.6
Net income (loss) attributable to stockholders	$ 4.4	$ (34.4)	$ (41.5)	$ (112)

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 326.8	$ 156.3
Work in process	16	0
Raw materials and supplies	127.2	49.5
Total inventory, net	$ 470	$ 205.8

Inventories (Details 2)

Inventories (Details 2) - Fair Value Adjustment to Inventory [Member] - USD ($) $ in Millions	3 Months Ended		5 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Arysta [Member]
Inventory [Line Items]
Fair value of assets			$ 39
Cost of Sales [Member] | Arysta [Member]
Inventory [Line Items]
Fair value of assets	$ 20.6			$ 36.5
Cost of Sales [Member] | CAS [Member]
Inventory [Line Items]
Fair value of assets				$ 20.2
Cost of Sales [Member] | Mac Dermid [Member]
Inventory [Line Items]
Fair value of assets		$ 12			$ 12

Property, Plant and Equipment54

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 308.1	$ 308.1		$ 308.1		$ 188.9
Less: accumulated depreciation	(41.9)	(41.9)		(41.9)		(18.1)
Construction in process	14.4	14.4		14.4		4.2
Property, plant and equipment, net	280.6	280.6		280.6		175
Depreciation expense		13.4	$ 5.4	21.5	$ 9
Assets acquired under capital lease	16	16		16		5.5
Land and Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	42.1	42.1		42.1		36.6
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	77.8	77.8		77.8		44.4
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	166.5	166.5		166.5		99
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	21.7	21.7		21.7		8.9
Excluding Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	266.2	266.2		266.2		$ 170.8
Performance Application's San Marcos, CA facility [Member]
Property, Plant and Equipment [Line Items]
Book value of asset held for sale	10.9	$ 10.9		$ 10.9
CAS [Member]
Property, Plant and Equipment [Line Items]
Equipment acquired	$ 13.2

Goodwill and Intangible Asset55

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Carrying value of indefinite-lived intangible assets other than goodwill	$ 238		$ 238		$ 69.3
Intangible assets weighted average useful life			15 years
Amortization of Intangible Assets	52.4	$ 16	$ 92.2	$ 29.3
2,015	198		198
2,016	211		211
2,017	211		211
2,018	211		211
2,019	211		211
2,020	$ 210		$ 210
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			20 years
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			12 years
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			20 years
Noncompete Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			5 years
Maximum [Member] | Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			30 years
Maximum [Member] | Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			14 years
Maximum [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			20 years
Maximum [Member] | Noncompete Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years
Minimum [Member] | Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			8 years
Minimum [Member] | Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years
Minimum [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years

Goodwill and Intangible Asset56

Goodwill and Intangible Assets (Details 2) $ in Millions	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill [Roll Forward]
Goodwill Balance	$ 1,405.3
Addition from acquisitions	2,200
Goodwill Balance	3,012.8
Performance Materials [Member]
Goodwill [Roll Forward]
Goodwill Balance	961.2
Addition from acquisitions	0
Purchase accounting adjustments	0
Foreign currency translation	(23.9)
Goodwill Balance	937.3
Graphic Solutions [Member]
Goodwill [Roll Forward]
Goodwill Balance	444.1
Addition from acquisitions	1,697.1
Purchase accounting adjustments	43.8
Foreign currency translation	(109.5)
Goodwill Balance	2,075.5
ArgoSolutions [Member]
Goodwill [Roll Forward]
Goodwill Balance	1,405.3
Addition from acquisitions	1,697.1
Purchase accounting adjustments	43.8
Foreign currency translation	(133.4)
Goodwill Balance	$ 3,012.8

Goodwill and Intangible Asset57

Goodwill and Intangible Assets (Details 3) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,823.2	$ 1,395.7
Accumulated Amortization and Foreign Exchange	(284)	(123.5)
Net Book Value	2,539.2	1,272.2
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	946.8	613.6
Accumulated Amortization and Foreign Exchange	(104.5)	(71.6)
Net Book Value	842.3	542
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,855.5	760.5
Accumulated Amortization and Foreign Exchange	(177)	(50.8)
Net Book Value	1,678.5	709.7
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	19	19.7
Accumulated Amortization and Foreign Exchange	(2.2)	(1)
Net Book Value	16.8	18.7
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1.9	1.9
Accumulated Amortization and Foreign Exchange	(0.3)	(0.1)
Net Book Value	$ 1.6	$ 1.8

Goodwill and Intangible Asset58

Goodwill and Intangible Assets Goodwill and Intangible Assets (Details 4) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill	$ 3,012.8	$ 1,405.3
AFS Americas Reporting Unit [Member]
Goodwill [Line Items]
Excess of the fair value of the reporting unit over its carrying value	11.80%
Goodwill	$ 73.2
Revenue growth forecast period	5 years
Long term revenue growth rate	3.00%
WACC	10.00%
AFS Americas Reporting Unit [Member] | Minimum [Member]
Goodwill [Line Items]
Revenue growth rate	4.20%
AFS Americas Reporting Unit [Member] | Maximum [Member]
Goodwill [Line Items]
Revenue growth rate	5.60%

Equity Compensation Plans (Deta

Equity Compensation Plans (Details) $ / shares in Units, $ in Millions	Mar. 19, 2015shares	Mar. 17, 2015$ / sharesshares	Mar. 06, 2014USD ($)shares	Apr. 23, 2013shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)person$ / sharesshares	Jun. 30, 2014USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Combined undiscounted maximum cash value of all RSUs | $			$ 7.1		$ 5		$ 5
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares of common stock that may be subject to grant awards (in shares)					15,500,000		15,500,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum approved shares of common stock for ESPP (in shares)			5,178,815
Total number of shares issued under ESPP (in shares)							25,966
Persons eligible to participate | person							573
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Canceled (in shares)							(25,984)
Restricted Stock Units (RSUs) [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)			213,402
Grant date fair value range (in usd per share) | $ / shares		$ 23.43
Restricted Stock Units (RSUs) [Member] | Director [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							84,242
Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							242,980
Performance Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							242,980
Restricted Stock Units Granted 17 March 2015 [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)		7,642
Grant date fair value range (in usd per share) | $ / shares		$ 27.05
Equity compensation expense | $					$ 0	$ (0.3)	$ (0.3)	$ (0.3)
Restricted Stock Units Granted 6 March 2014 [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)			329,823
Equity compensation expense | $					$ (0.9)	$ (0.1)	$ (1.4)	$ (0.1)
Minimum [Member] | Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value range (in usd per share) | $ / shares					$ 26.17		$ 26.17
Vesting period							24 months
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value range (in usd per share) | $ / shares					$ 27.05		$ 27.05
Vesting period							57 months 15 days
Deferred Bonus [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity compensation expense | $					$ (0.3)		$ (0.8)
Allotted bonus total amount | $					46.5		46.5
Amount of LTCB subject to common shares | $					$ 12.5		$ 12.5
Deferred Bonus [Member] | Minimum [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							24 months 15 days
Deferred Bonus [Member] | Maximum [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							60 months
Platform Specialty Products [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares issued under ESPP (in shares)	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years
Option to acquire shares (in shares)				75,000

Equity Compensation Plans (De60

Equity Compensation Plans (Details 2) - $ / shares	6 Months Ended
	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Total [Roll Forward]
Total, beginning balance (in shares)	721,933
Total, Granted (in shares)	464,024
Total, Exercised (in shares)	(75,000)
Total, Forfeited (in shares)	(25,984)
Total, ending balance (in shares)	1,084,973
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options, beginning balance (in shares)	250,000
Stock Options, Exercised (in shares)	(75,000)
Stock Options, ending balance (in shares)	175,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	142,110
Granted (in shares)	250,622
Exercised (in shares)	0
Canceled (in shares)	(25,984)
Ending balance (in shares)	366,748
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, beginning balance (in usd per share)	$ 329,823
Weighted Average Exercise Price, Granted (in usd per share)	213,402
Weighted Average Exercise Price, Canceled (in usd per share)	0
Weighted Average Exercise Price, ending balance (in usd per share)	$ 543,225

Pension, Post-Retirement and 61

Pension, Post-Retirement and Post-Employment Plans (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Defined Benefit Plan Disclosure [Line Items]
Service cost			$ 0
Pension Plan [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	0	$ 0
Other Postretirement Benefit Plan [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost on the projected benefit obligation	100,000	100,000	200,000	200,000
Net periodic (benefit) cost	100,000	100,000	200,000	200,000
Other Postretirement Benefit Plan [Member] | Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost on the projected benefit obligation	0	0	0	0
Net periodic (benefit) cost	0	0	0	0
Pension And SERP Benefits [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0		0
Interest cost on the projected benefit obligation	1,600,000	1,700,000	3,200,000	3,400,000
Expected return on plan assets	(2,400,000)	(2,400,000)	(4,800,000)	(4,800,000)
Net periodic (benefit) cost	(800,000)	(700,000)	(1,600,000)	(1,400,000)
Pension And SERP Benefits [Member] | Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	200,000	200,000	400,000	400,000
Interest cost on the projected benefit obligation	500,000	800,000	1,000,000	1,600,000
Expected return on plan assets	(500,000)	(900,000)	(1,000,000)	(1,800,000)
Net periodic (benefit) cost	$ 200,000	$ 100,000	$ 400,000	$ 200,000

Debt, Capital Leases, Financi62

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Details)	Feb. 13, 2015USD ($)	Feb. 13, 2015EUR (€)	Nov. 03, 2014USD ($)	Nov. 03, 2014EUR (€)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Feb. 13, 2015EUR (€)	Feb. 02, 2015USD ($)	Feb. 02, 2015EUR (€)	Nov. 03, 2014EUR (€)	Oct. 01, 2014USD ($)
Debt Instrument [Line Items]
Weighted average interest rate, short term debt					3.41%		3.41%
Debt issuance costs reclassification from assets to contra-liabilities					$ 48,600,000		$ 48,600,000		$ 10,300,000
Debt issuance costs reclassification from assets to current contra-liabilities					$ 4,700,000		$ 4,700,000		1,900,000
Maximum percentage of letter of credit obligations exceeding revolving credit commitments					25.00%		25.00%
Voting capital stock pledged of domestic subsidiaries							100.00%
Voting capital stock pledged of non-domestic subsidiaries							65.00%
Borrowings under lines of credit, weighted average interest rate of 3.29% at June 30, 2015					$ 22,400,000		$ 22,400,000		0
Overdraft facility capacity							367,000,000		195,000,000
Factoring agreements total current capacity					244,000,000		244,000,000
Factoring agreements qualifying for sales treatment					90,600,000		90,600,000		0
Factoring agreements recorded in accounts receivable					$ (46,500,000)		$ (46,500,000)		0
First Lien Term Loan [Member]
Debt Instrument [Line Items]
Long term debt | €													€ 205,000,000
USD Incremental Loans [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate					4.26%		4.26%
Long term debt					$ 291,700,000		$ 291,700,000		292,700,000
Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate					4.26%		4.26%
Long term debt					$ 121,900,000		$ 121,900,000		121,700,000
New Tranche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 500,000,000
Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Stated interest rate					4.25%		4.25%
Spread on variable rate							3.25%
Weighted average interest rate					4.25%		4.25%
Revolving credit facility | €										€ 287,000,000
Long term debt					$ 225,700,000		$ 225,700,000		246,200,000
Multicurrency revolving credit facility was increase | €		€ 83,000,000
Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.75%		4.75%
Spread on variable rate							3.75%
Weighted average interest rate					4.75%		4.75%
Long term debt					$ 482,100,000		$ 482,100,000		0
Euro Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.25%		4.25%
Spread on variable rate							3.25%
Weighted average interest rate					4.25%		4.25%
Long term debt					$ 90,300,000		$ 90,300,000		0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility	163,000,000
Multicurrency revolving credit facility was increase	75,000,000
Borrowed under U.S. Dollar revolving credit facility for acquisition	160,000,000
Outstanding letters of credit					$ 7,300,000		$ 7,300,000		1,000,000
Revolving Credit Facility, Multi Currency [Member]
Debt Instrument [Line Items]
Revolving credit facility	163,000,000
Multicurrency revolving credit facility was increase	$ 75,000,000
Eurodollar [Member] | Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.50%	3.50%
Eurodollar [Member] | Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.75%	3.75%
Eurodollar [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.00%	3.00%
Base Rate [Member] | Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.50%	2.50%
Base Rate [Member] | Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.75%	2.75%
Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.00%	2.00%
Maximum [Member]
Debt Instrument [Line Items]
Ratio of debt to EBITDA							1
Maximum [Member] | Overdraft Facility [Member]
Debt Instrument [Line Items]
Stated interest rate					25.00%		25.00%
Minimum [Member]
Debt Instrument [Line Items]
Ratio of debt to EBITDA							6.5
Minimum [Member] | Overdraft Facility [Member]
Debt Instrument [Line Items]
Stated interest rate					0.45%		0.45%
Barclays Bank PLC [Member]
Debt Instrument [Line Items]
Second amendment increase in credit facility														$ 300,000,000
Chemtura [Member] | New Tranche B Term Loans [Member]
Debt Instrument [Line Items]
Long term debt			$ 130,000,000
Chemtura [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility			87,500,000
Borrowed under the U.S. Dollar and multicurrency revolving credit facility			60,000,000	€ 55,000,000
Chemtura [Member] | Revolving Credit Facility, Multi Currency [Member]
Debt Instrument [Line Items]
Revolving credit facility			$ 87,500,000
Arysta [Member] | New Tranche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 500,000,000
Original issue discount percentage	$ 0.01
Arysta [Member] | Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Original issue discount percentage | €										0.02
Increase in Euro tranche term loan facility | €										€ 83,000,000
Notes Payable to Banks [Member] | USD Notes [Member]
Debt Instrument [Line Items]
Stated interest rate					6.50%		6.50%				6.50%	6.50%
Long term debt					$ 1,079,500,000		$ 1,079,500,000		0
Gross debt, long term											$ 1,100,000,000
Notes Payable to Banks [Member] | Euro Notes [Member]
Debt Instrument [Line Items]
Stated interest rate					6.00%		6.00%				6.00%	6.00%
Long term debt					$ 383,400,000		$ 383,400,000		0
Gross debt, long term | €												€ 350,000,000
Original issue premium											$ 1,000,000
Secured Debt [Member] | First Lien Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate					4.26%		4.26%
Long term debt					$ 739,300,000		$ 739,300,000		743,000,000
Other Operating Income (Expense) [Member]
Debt Instrument [Line Items]
Factoring agreement program gains					0		200,000	$ 0
Factoring fees					500,000	$ 0	1,200,000	$ 0
Financial Guarantee [Member]
Debt Instrument [Line Items]
Financial guarantees					$ 23,500,000		$ 23,500,000		$ 0

Debt, Capital Leases, Financi63

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Details 2) € in Millions, $ in Millions	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Nov. 03, 2014EUR (€)
Debt Instrument [Line Items]
Borrowings under lines of credit, weighted average interest rate of 3.29% at June 30, 2015	$ 22.4	$ 0
Capital lease obligations	4.5	2
Long-Term Debt And Debt Issuance Costs, Gross	3,418.4	1,405.6
Less: current portion debt and capital lease obligations	(16.8)	(13.2)
Total long-term debt and capital lease obligations	3,401.6	1,392.4
USD Notes [Member] | Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Long term debt	1,079.5	0
Euro Notes [Member] | Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Long term debt	383.4	0
First Lien Term Loan [Member]
Debt Instrument [Line Items]
Long term debt | €			€ 205
First Lien Term Loan [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Long term debt	739.3	743
USD Incremental Loans [Member]
Debt Instrument [Line Items]
Long term debt	291.7	292.7
Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	121.9	121.7
Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	482.1	0
Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Long term debt	225.7	246.2
Euro Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 90.3	$ 0

Debt, Capital Leases, Financi64

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (details 3) $ in Millions	Jun. 30, 2015USD ($)
Debt Disclosure [Abstract]
2015 - remaining	$ 10.9
2,016	20.8
2,017	20.5
2,018	20.4
2,019	20.4
2,020	1,892.6
Thereafter	1,492.1
Total	$ 3,477.7

Derivative Instruments (Details

Derivative Instruments (Details) € in Millions, £ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015EUR (€)	Jun. 30, 2015GBP (£)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative financial instruments revaluation, net of tax	$ 0	$ (100,000)	$ 0	$ (100,000)
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency forward contract	139,000,000		139,000,000
Foreign Exchange Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative financial instruments revaluation, net of tax	1,400,000	300,000	1,400,000	500,000
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gains (losses) recorded to other comprehensive income related to foreign currency hedges	0	$ 200,000	0	$ 200,000
United States of America, Dollars [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency forward contract	$ 125,000,000		$ 125,000,000
United Kingdom, Pounds [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency forward contract | £						£ 5.9
Euro Member Countries, Euro [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency forward contract | €					€ 4.2

Derivative Instruments (Detai66

Derivative Instruments (Details 2) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Total derivative contracts	$ 0.7	$ (0.1)
Prepaid Expenses and Other Current Assets [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts	0.7	0
Accued Expenses And Other Current Liabilities [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts	$ 0	$ 0.1

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
NAV Redemptions			$ 1
Non-cash fair value adjustment to contingent consideration	$ (900,000)	$ (10,800,000)	$ (3,600,000)	$ (23,800,000)
Percentage change in rate affecting component measurement			0.50%
Measurement component change affected by change in discount rate			$ 1,000,000
Mac Dermid [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term contingent consideration	100,000,000		$ 100,000,000
Price performance metrics period			7 years
EBITDA related earnout include a discount rate			1.80%
Business acquisition expected future value payments			$ 60,000,000
Selling, General and Administrative Expenses [Member] | Mac Dermid [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Non-cash fair value adjustment to contingent consideration	$ 900,000	$ 10,800,000	$ 3,600,000	$ 23,800,000

Fair Value Measurements (Deta68

Fair Value Measurements (Details 2) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Estimate of Fair Value Measurement [Member]
Asset Category
Money market accounts	$ 29.2	$ 15.4
Available for sale equity securities	2.3	2.3
Derivatives	0.7
Total	32.2	17.7
Liability Category
Long term contingent consideration	67.5	63.9
Derivatives		0.1
Total	67.5	64
Fair Value, Inputs, Level 1 [Member]
Asset Category
Money market accounts	29.2	15.4
Available for sale equity securities	1.5	1.5
Derivatives	0
Total	30.7	16.9
Liability Category
Long term contingent consideration	0	0
Derivatives		0
Total	0	0
Fair Value, Inputs, Level 2 [Member]
Asset Category
Money market accounts	0	0
Available for sale equity securities	0.8	0.8
Derivatives	0.7
Total	1.5	0.8
Liability Category
Long term contingent consideration	0	0
Derivatives		0.1
Total	0	0.1
Fair Value, Inputs, Level 3 [Member]
Asset Category
Money market accounts	0	0
Available for sale equity securities	0	0
Derivatives	0
Total	0	0
Liability Category
Long term contingent consideration	67.5	63.9
Derivatives		0
Total	$ 67.5	$ 63.9

Fair Value Measurements (Deta69

Fair Value Measurements (Details 3) € in Millions, $ in Millions	Jun. 30, 2015USD ($)	Feb. 02, 2015USD ($)	Feb. 02, 2015EUR (€)	Dec. 31, 2014USD ($)	Nov. 03, 2014EUR (€)
Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Capital lease obligations	$ 4.5			$ 2
Long term debt	3,418.4			1,405.6
Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Capital lease obligations	4.5			2.6
Long term debt	3,454.7			1,364
First Lien Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt | €					€ 205
USD Incremental Loans [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	291.7			292.7
USD Incremental Loans [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	291.7			292.7
USD Incremental Loans [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	291.4			283.9
Tranche B Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	121.9			121.7
Tranche B Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	121.9			121.7
Tranche B Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	121.8			118
Traunche B-2 Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	482.1			0
Traunche B-2 Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	482.1			0
Traunche B-2 Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	481.5			0
Euro Tracnche Term Loans [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	225.7			246.2
Euro Tracnche Term Loans [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	225.7			246.2
Euro Tracnche Term Loans [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	225.4			238.8
Euro Traunche B-2 Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	90.3			0
Euro Traunche B-2 Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	90.3			0
Euro Traunche B-2 Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	90.2			0
Notes Payable to Banks [Member] | USD Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term		$ 1,100
Long term debt	1,079.5			0
Notes Payable to Banks [Member] | USD Notes [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	1,079.5			0
Notes Payable to Banks [Member] | USD Notes [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	1,117.3			0
Notes Payable to Banks [Member] | Euro Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term | €			€ 350
Long term debt	383.4			0
Notes Payable to Banks [Member] | Euro Notes [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	383.4			0
Notes Payable to Banks [Member] | Euro Notes [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	384.3			0
Secured Debt [Member] | First Lien Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	739.3			743
Secured Debt [Member] | First Lien Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	739.3			743
Secured Debt [Member] | First Lien Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 738.3			$ 720.7

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jun. 29, 2015	Jun. 23, 2015	Mar. 19, 2015	Feb. 13, 2015	Dec. 31, 2014	May. 22, 2013	Apr. 23, 2013	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 13, 2014	Jan. 23, 2014
Class of Stock [Line Items]
Price of shares issued (in usd per share)	$ 11							$ 26.50		$ 19,000,000	$ 11	$ 26.50	$ 19,000,000
Issuance of common shares to directors for exercise of stock options (in shares)												75,000
Proceeds from Issuance of Common Stock	$ 483,000,000											$ 469,400,000	$ 473,600,000
Number of preferred shares authorized in amendment (in shares)														5,000,000
Liquidation preference per share								$ 1,000				$ 1,000
Share price (in usd per share)															$ 0.01
Preferred stock outstanding (in shares)								$ 0	$ 0	$ 300,200,000	$ 0
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014					10,050,290
Dividend price (in usd per share)					$ 22.85
Total number of shares of common stock originally issuable upon the exchange of PDH common stock pursuant to the RHSA (in shares)								8,800,000
Net income allocated to Retaining Holders										$ 1,800,000
Conversion price (in usd per share)								$ 27.14				$ 27.14
Arysta [Member]
Class of Stock [Line Items]
Volume weighted average price period				10 days
Equity Instruments				$ 645,900,000
Noncontrolling interest acquired				$ 24,600,000
Maximum share conversion (in shares)				22,107,590
Mac Dermid [Member]
Class of Stock [Line Items]
Equity Instruments								$ 97,500,000				$ 97,500,000
Net income allocated to Retaining Holders								$ 2,000,000				$ 1,200,000	$ 3,100,000
Noncontrolling interest percentage					6.67%			6.36%		6.76%		6.36%	6.76%
Platform Specialty Products [Member] | Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
Option to acquire shares (in shares)							75,000
Option exercised to acquire shares (in shares)			75,000
PDH [Member]
Class of Stock [Line Items]
Rate PDH Common stock that may be exchanged for shares of common stock												25.00%
Common stock issued in connection with exchange of PDH common stock (in shares)								561,577				561,577
Weighted Average [Member]
Class of Stock [Line Items]
Share price (in usd per share)					$ 23.16
Redeemable Series B Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity designated (in shares)								600,000				600,000
Temporary equity issued (in shares)					0			600,000				600,000
Temporary equity outstanding (in shares)					0			600,000				600,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Number of preferred shares authorized in amendment (in shares)														2,000,000
Preferred shares, shares issued (in shares)					2,000,000			2,000,000				2,000,000
Preferred shares, shares outstanding (in shares)					2,000,000			2,000,000				2,000,000
Series A Preferred Stock [Member] | Founders Entities [Member]
Class of Stock [Line Items]
Preferred stock outstanding (in shares)						$ 2,000,000
Series A Preferred Stock To Common Stock [Member]
Class of Stock [Line Items]
Maximum share conversion												1
Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, shares (in Shares)		18,226,414						406,217	21,316	15,800,000	3,959
Price of shares issued (in usd per share)		$ 26.50
Issuance of common shares to directors for exercise of stock options (in shares)									75,000
Payments of Stock Issuance Costs	$ 14,800,000
Preferred stock outstanding (in shares)										$ 200,000
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014									10,050,290
Common Stock [Member] | Underwriter Options [Member]
Class of Stock [Line Items]
Issuance of common shares to directors for exercise of stock options (in shares)		2,377,358

Accumulated Other Comprehensi71

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ (547.8)	$ 4.7	$ (130.6)	$ 1.3
Other comprehensive income (loss) before reclassifications, net	160.2	18.5	(256.5)	22
Reclassifications, pretax	0	(0.2)	0	(0.3)
Tax benefit reclassified	0	0.1	(0.5)	0.1
Ending balance	(387.6)	23.1	(387.6)	23.1
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(547.5)	2.7	(122.2)	(0.6)
Other comprehensive income (loss) before reclassifications, net	161.5	19.7	(263.8)	23
Reclassifications, pretax	0	0	0	0
Tax benefit reclassified	0	0	0	0
Ending balance	(386)	22.4	(386)	22.4
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(15.4)	2	(14.9)	1.8
Other comprehensive income (loss) before reclassifications, net	0	0	0	0.2
Reclassifications, pretax	0	0	0	0
Tax benefit reclassified	0	0	(0.5)	0
Ending balance	(15.4)	2	(15.4)	2
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	0	0	0.1	0
Other comprehensive income (loss) before reclassifications, net	0.3	0.1	0.2	0.1
Reclassifications, pretax	0	(0.1)	0	(0.1)
Tax benefit reclassified	0	0	0	0
Ending balance	0.3	0	0.3	0
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	0	0	0	0.1
Other comprehensive income (loss) before reclassifications, net	0	0	0	0
Reclassifications, pretax	0	(0.1)	0	(0.2)
Tax benefit reclassified	0	0.1	0	0.1
Ending balance	0	0	0	0
Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	15.1	0	6.4	0
Other comprehensive income (loss) before reclassifications, net	(1.6)	(1.3)	7.1	(1.3)
Reclassifications, pretax	0	0	0	0
Tax benefit reclassified	0	0	0	0
Ending balance	$ 13.5	$ (1.3)	$ 13.5	$ (1.3)

Earnings Per Share (Details) -

Earnings Per Share (Details) - Weighted Average Shares Outstanding - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common shareholders (in Dollars)		$ (12.2)	$ (0.4)	$ (38.9)	$ (7.8)
Basic weighted average common shares outstanding (in shares)		192,800,000	128,600,000	192,300,000	117,900,000
Weighted average shares (in shares)	[1]	0	0	0	0
Dilutive weighted average common shares outstanding (in shares)		192,800,000	128,600,000	192,300,000	117,900,000
Basic (in usd per share)		$ (0.06)	$ 0	$ (0.20)	$ (0.07)
Diluted (in usd per share)		$ (0.06)	$ 0	$ (0.20)	$ (0.07)
share adjustments (in shares)		36,687,000	22,857,000	31,236,000	25,635,000
Share Adjustment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
share adjustments (in shares)				0
[1]	No share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive.

Earnings Per Share (Details 2)

Earnings Per Share (Details 2) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	36,687	22,857	31,236	25,635
Contingently Issuable Shares For The Founder Preferred Share Dividend Right [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	2,789	11,279	2,789	11,279
Shares Issualble Upon Conversion Of Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	0	0	0	2,243
Shares Issuable Upon Conversion of PDH Non-controlling Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	8,213	8,775	8,213	8,775
Shares Issuable Upon Conversion Of Founder Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	2,000	2,000	2,000	2,000
Shares Issuable Upon Conversion Of Series B Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	22,108	0	16,733	0
Contingently Issuable for the Contingent Consideration [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	1,347	713	1,333	713
Shares Issuable Upon Conversion Of 401K Exchange Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	0	0	0	544
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	69	88	79	80
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	161	2	89	1

Operating Lease Commitments (De

Operating Lease Commitments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Total rent expense	$ 6.1	$ 2.5	$ 10.4	$ 5
2,015					$ 7
2,016					9.5
2,017					6.5
2,018					4.8
2,019					3.8
2,020					3.1
Thereafter					12.8
Total					$ 47.5

Contingencies, Environmental 75

Contingencies, Environmental and Legal Matters (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Loss Contingency Accrual [Roll Forward]
AROs, beginning of period	$ 17.4	$ 4.9	$ 18.5	$ 4.8
Acquisitions	0.4	0.3	0.4	0.3
Accretion expense	0.2	0.2	0.5	0.3
Remeasurements	(0.7)	0	(0.7)	0
Foreign currency adjustments	0.4	0	(1)	0
AROs, end of period	$ 17.7	$ 5.4	$ 17.7	$ 5.4

Contingencies, Environmental 76

Contingencies, Environmental and Legal Matters (Details 2) BRL in Millions, $ in Millions	Apr. 03, 2015USD ($)	Feb. 19, 2015USD ($)	Feb. 13, 2015USD ($)shares	Apr. 30, 2014USD ($)defendant	Nov. 30, 2011defendant	Jun. 30, 2009defendant	Jun. 30, 2015USD ($)BRL / $	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)employeedefendantBRL / $	Jun. 30, 2015BRLemployeedefendant	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Jun. 30, 2015BRLBRL / $	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Loss Contingencies [Line Items]
Asset retirement obligations							$ 17.7	$ 5.4	$ 17.7		$ 5.4	$ 18.5		$ 17.4	$ 4.9	$ 4.8
Reserves for environmental matters							2.1		2.1			4.5
Estimate of possible loss in legal proceedings							$ 5.9		$ 5.9			4.4
Potential litigation loss exchange rate | BRL / $							0.3223		0.3223				0.3223
Contest of tax assessment							$ 13.3		$ 13.3				BRL 41.3
Legal settlement							$ 16	$ 0	16		$ 0
Settled Litigation [Member]
Loss Contingencies [Line Items]
Legal settlement		$ 25
Amount awarded	$ 16
Arysta [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants | defendant					6,000,000	26,000,000
Compensation sought									16.1	BRL 50
Remediation amount sought									$ 22.9	BRL 70.9
Agricola Colonet, SA de CV [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Compensation sought												$ 11.3
Arysta [Member]
Loss Contingencies [Line Items]
Series B preferred stock issued (in shares)			$ 600
Maximum share conversion (in shares) | shares			22,107,590
Maximum share conversion amount			$ 600
Volume weighted average price period			10 days
Arysta [Member] | Series B Preferred Stock [Member]
Loss Contingencies [Line Items]
Series B preferred stock issued (in shares)			$ 600
Health Problems From Employment Site [Member] | Arysta [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants | defendant									80	80
Compensation sought									$ 55.9	BRL 173.3
Number of former employees | employee									13	13
Health Risk From Product Exposure [Member] | Arysta LifeScience North America, LLC [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants | defendant				30
Compensation sought				$ 13.2

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Interim Period, Costs Not Allocable [Line Items]
Income tax expense	$ (0.2)	$ (4.1)	$ 24.5	$ (1.9)
Effective income tax rate	2.70%	158.20%	(224.70%)	30.50%
Loss before income taxes and non-controlling interests	$ (9.3)	$ (2.6)	$ (10.9)	$ (6.4)
Tax charge due to change in valuation allowance	4.8
Tax reserves	2.4
Valuation allowance on foreign tax credit carryovers		$ 23.8		$ 23.8
Unrecognized tax benefit	67.8		67.8			$ 27.7
Reduction in effective tax rate	36.3		36.3
Accrued interest and penalties related to unrecognized tax benefits	9.7		9.7			$ 4.7
Interest and penalties recognized	0.1		0.4
Possible reduction in tax benefits from lapse of applicable statute of limitations	$ 3.3		$ 3.3
State and Local Jurisdiction [Member]
Interim Period, Costs Not Allocable [Line Items]
Valuation allowance					$ 19

Income Taxes Income Taxes (Deta

Income Taxes Income Taxes (Details 2) - Earliest Tax Year [Member]	6 Months Ended
	Jun. 30, 2015
Administration of the Treasury, Belgium [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,008
Secretariat of the Federal Revenue Bureau of Brazil [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
State Administration of Taxation, China [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,011
Ministry of the Economy, Finance and Industry, France [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,010
National Tax Agency, Japan [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
Mexican Tax Authority [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
South Africa Revenue Service (SARS) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
Her Majesty's Revenue and Customs (HMRC) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,008
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,011

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Variable Interest Entity [Line Items]
Total assets	$ 8,546.4	$ 4,547.3
Variable Interest Entity, Primary Beneficiary [Member] | Subsidiaries [Member]
Variable Interest Entity [Line Items]
Interest in entity	45.00%
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member]
Variable Interest Entity [Line Items]
Equity of equity method investee	$ 4.1
Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities	1
Total assets	$ 14.6
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member] | Sale Of Platform Products [Member] | Product Concentration Risk [Member]
Variable Interest Entity [Line Items]
Percentage of sales that are Platform products	94.00%
Variable Interest Entity, Not Primary Beneficiary [Member] | Minority Shareholder Of SPIA [Member]
Variable Interest Entity [Line Items]
Interest in entity	50.90%
Variable Interest Entity, Not Primary Beneficiary [Member] | SPIA [Member]
Variable Interest Entity [Line Items]
Ownership percentage of equity investment	31.95%
Equity of equity method investee	$ 4.3
Equity method investment on balance sheet	1.3
Total assets	$ 4.3
Variable Interest Entity, Not Primary Beneficiary [Member] | SPIA [Member] | Sale Of Platform Products [Member] | Product Concentration Risk [Member]
Variable Interest Entity [Line Items]
Percentage of sales that are Platform products	90.00%

Variable Interest Entities (D80

Variable Interest Entities (Details 2) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Variable Interest Entity [Line Items]
Property, plant and equipment, net	$ 280.6	$ 175
Other assets	88.4	49
Total assets	8,546.4	4,547.3
Current liabilities	858	240.7
Other long-term liabilities	104.1	56.6
Total liabilities	5,152	$ 1,994.7
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	0
Other current assets	13.1
Property, plant and equipment, net	1.2
Other assets	0.3
Total assets	14.6
Current liabilities	10.5
Total liabilities	$ 10.5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Mac Dermid [Member]
Related Party Transaction [Line Items]
Price exchange rate (in usd per share)	$ 11		$ 11
Contingent purchase payable	$ 100,000,000		$ 100,000,000
Price performance metrics period			7 years
Noncontrolling interest percentage	6.36%	6.76%	6.36%	6.76%	6.67%
Mariposa Capital [Member]
Related Party Transaction [Line Items]
Automatic renewal period			1 year
Agreement renewal period			90 days
Advisory fees	$ 500,000	$ 500,000	$ 1,000,000	$ 1,000,000
Annual Fees [Member] | Mariposa Capital [Member]
Related Party Transaction [Line Items]
Annual fee			$ 2,000,000

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 12.1	$ 0.4	$ 13.7	$ 0.4
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.2	0	1.2	0
Selling, Technical, General And Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	10.9	0.4	12.5	0.4
Performance Applications [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.4	0.4	2.9	0.4
Agricultural Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	10.7	$ 0	10.8	$ 0
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring liabilities	$ 0.7		$ 0.7		$ 1.6

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Sales (from external customers):
Net Sales	$ 675.1	$ 189.1	$ 1,209.9	$ 372.8
Adjusted EBITDA:
Operating profit	44	5.6	46.2	9.6
Adjusted EBITDA	167.6	48.2	298.1	94.1
Performance Materials [Member]
Net Sales (from external customers):
Net Sales	181.5	189.1	361.8	372.8
Adjusted EBITDA:
Operating profit	53.9	48.2	102.4	94.1
Graphic Solutions [Member]
Net Sales (from external customers):
Net Sales	493.6	0	848.1	0
Adjusted EBITDA:
Operating profit	$ 113.7	$ 0	$ 195.7	$ 0

Segment Information (Details 2)

Segment Information (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting [Abstract]
Adjusted EBITDA	$ 167.6	$ 48.2	$ 298.1	$ 94.1
Interest expense	(52.5)	(7.9)	(93)	(15.7)
Depreciation and amortization expense	(66.1)	(21.4)	(114.3)	(38.3)
Restructuring and related expenses	(12.1)	(0.4)	(13.7)	(0.4)
Manufacturer's profit in inventory adjustment	(20.7)	0	(56.7)	(12)
Acquisition transaction costs	(24.1)	(10.5)	(55.4)	(10.5)
Non-cash fair value adjustment to contingent consideration	(0.9)	(10.8)	(3.6)	(23.8)
Legal settlement	16	0	16	0
Acquisition put option expiration	0	0	3	0
Foreign exchange gains on foreign denominated external and internal debt	(17.9)	0	6.1	0
Other income	1.4	0.2	2.6	0.2
Loss before income taxes and non-controlling interest	(9.3)	(2.6)	(10.9)	(6.4)
Income tax benefit (expense)	0.2	4.1	(24.5)	1.9
Net income attributable to the non-controlling interests	3.1	1.9	3.5	3.3
Net loss attributable to stockholders	$ (12.2)	$ (0.4)	$ (38.9)	$ (7.8)

Subsequent Events (Details)

Subsequent Events (Details) £ / shares in Units, € in Millions, £ in Millions, $ in Millions	Jul. 13, 2015USD ($)£ / shares£ / $shares	Aug. 05, 2015USD ($)	Aug. 05, 2015EUR (€)	Jul. 31, 2015USD ($)	Jul. 31, 2015GBP (£)	Jul. 13, 2015GBP (£)£ / $	Jul. 10, 2015	Jun. 30, 2015BRL / $
Subsequent Event [Line Items]
Foreign currency exchange rate | BRL / $								0.3223
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of pence per ordinary share of acquiree | £ / shares	£ 0.503
Mac Dermid [Member] | Alent [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Acquiree shareholders number of acquiring company shares exchanged in lieu of cash	0.31523
New share issuance limited to acquiree share capital	21.90%
Acquiree share capital	£ 2,100					£ 1,350
Irrevocable undertaking ownership (in shares) | shares	58,432,694
Foreign currency exchange rate							1.5517
Break-Up Fee [Member] | Alent [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Break-up fee | £						£ 27
Foreign Exchange Forward [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Foreign currency exchange rate | £ / $	1.5487					1.5487
Percentage of forward at fixed exchange rate				50.00%	50.00%
Percentage of forward at floating rate				50.00%	50.00%
Debt amount affected by interest rate swap				$ 1,640	£ 1,060
Notes Payable to Banks [Member] | USD Notes [Member] | Interest Rate Swap [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt amount affected by interest rate swap		$ 1,200
Interest rate swap rate		1.96%	1.96%
Notes Payable to Banks [Member] | Euro Notes [Member] | Interest Rate Swap [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt amount affected by interest rate swap | €			€ 286
Interest rate swap rate		1.20%	1.20%
Maximum [Member] | Foreign Exchange Forward [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Exchange rate on 50% of forward contract | £ / $	1.6244					1.6244
Unsecured Debt [Member] | Letter of Credit [Member] | Alent [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Revolving credit facility	£ 1,880